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ABSTRACT OF THE DISSERTATION
Mitochondrial Dynamics Controls T Cell Fate Through Metabolic Programming
by
Michael D. Buck
Doctor of Philosophy in Biology and Biomedical Sciences
Immunology
Washington University in St. Louis, 2017
Professor Erika L. Pearce, Chair
Professor Eugene M. Oltz, Co-chair

Activated effector T (TE) cells augment anabolic pathways of metabolism, such as aerobic
glycolysis, while memory T (TM) cells engage catabolic pathways, like fatty acid oxidation
(FAO). However, signals that drive these differences remain unclear. Mitochondria are metabolic
organelles that actively transform their ultrastructure. Therefore, we questioned whether
mitochondrial dynamics controls T cell metabolism. We show that TE cells have punctate
mitochondria, while TM cells maintain fused networks. The fusion protein Opa1 is required for
TM, but not TE cells after infection, and enforcing fusion in TE cells imposes TM cell
characteristics and enhances antitumor function. Our data suggest that, by altering cristae
morphology, fusion in TM cells configures electron transport chain (ETC) complex associations
favoring oxidative phosphorylation (OXPHOS) and FAO, while fission in TE cells leads to
cristae expansion, reducing ETC efficiency and promoting aerobic glycolysis. Thus
mitochondrial remodeling is a signaling mechanism that instructs T cell metabolic programming.

ix

Chapter 1: T Cell Metabolism Drives Immunity
Published in the August 24th, 2015 issue of Journal of Experimental Medicine
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Abstract

Lymphocytes must adapt to a wide array of environmental stressors as part of their normal
development, during which they undergo a dramatic metabolic remodeling process. Research in
this area has yielded surprising findings on the roles of diverse metabolic pathways and
metabolites, which have been found to regulate lymphocyte signaling and influence
differentiation, function and fate. In this review, we integrate the latest findings in the field to
provide an up-to-date resource on lymphocyte metabolism.

Introduction

“Part of the secret of success in life is to eat what you like and let the food fight it out inside.” –
Mark Twain

Simply stated, we are what we eat. Our genetics coupled with environmental influences dictate
how we metabolize the nutrients we consume and shape our growth, function, and overall health.
The same principles hold true at the cellular level. Just as a track runner quickly engages their
muscles to propel themselves from rest to sprint in response to a starting gun, pathogen-derived
or inflammatory signals drive T cells out of quiescence, resulting in rapid modulation of gene
expression and the acquisition of new functions. These changes range from increased production
of cytokines and cytolytic molecules to the ability to undergo cell division and migration.
Intimately integrated into this program of activation is the regulation of cellular metabolism.
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The engagement of specific metabolic pathways profoundly affects cell differentiation and
function. Metabolic reprogramming is controlled by key receptor signaling events and growth
factor cytokines, as well as availability of nutrients. In addition, metabolic products provide
substrates that can alter the functional fate of a cell through post-translational modifications
(PTMs) or epigenetic remodeling. Several recent articles have covered these and other emerging
topics in T cell metabolism (Bird, 2015; Chapman and Chi, 2014; Lochner et al., 2015;
O'Sullivan and Pearce, 2015; Palmer et al., 2015; Ramsay and Cantrell, 2015; Ron-Harel et al.,
2015). In this review, we provide a general but comprehensive overview of lymphocyte
metabolism integrated with current research. Our focus will be on data and concepts derived
primarily from T cell studies with tie-ins from other fields when relevant.
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T cell development and quiescence

Although the bulk of T-cell metabolism research centers on mature T cells, even at their
inception and throughout their development, T cells cycle through states of metabolic quiescence
and activation. Hematopoietic stem cell progenitors that are double negative (DN) for CD4 and
CD8 co-receptors migrate from the bone marrow and seed the thymus where they rearrange their
antigen receptor gene loci to produce a functional T cell receptor (TCR). Signals from the
receptor Notch1 maintain cell survival and are required to promote T-cell lineage commitment
(Maillard et al., 2006; Pui et al., 1999; Radtke et al., 1999). Induced deletion of Notch1 during
neonatal development results in arrest at the most immature DN1 (CD44+CD25-) stage (Radtke
et al., 1999), while enforced expression of constitutively active Notch1 in bone marrow cells
blocks B cell differentiation and instead causes the ectopic development of CD4+CD8+ double
positive (DP) T cells (Pui et al., 1999).

Successful expression of TCRβ with pTα and CD3 forms the pre-TCR and signals with Notch1
to drive cells out of quiescence as they enter β-selection (Ciofani et al., 2004; Ciofani and
Zuniga-Pflucker, 2005; Saint-Ruf et al., 1994). RAG recombinase expression declines and
expression of the transferrin receptor CD71 and other nutrient transporters are induced as the
cells proliferate (Ciofani and Zuniga-Pflucker, 2005; Kelly et al., 2007). Signaling from the preTCR, Notch1, and the chemokine receptor CXCR4 converge to activate phosphatidylinositol 3kinase (PI3K); this stimulates the switch to anabolic metabolism (processes that supports the
biosynthetic demands of proliferation) (Ciofani and Zuniga-Pflucker, 2005; Janas et al., 2010).
Increased expression of the glucose transporter Glut1 is required during this stage and its
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expression is dependent on activation of the kinase Akt by PI3K (Juntilla et al., 2007; Swainson
et al., 2005; Wieman et al., 2007). PI3K-Akt signaling also activates the mechanistic target of
rapamycin (mTOR), and signals from this kinase augment the glycolytic metabolism used to
support cell growth and proliferation (MacIver et al., 2013).

Disruptions in PI3K signaling also affect the transition of DP thymocytes to single positive CD4
and CD8 T cells and the development of natural killer T (NKT) cells, which require sustained
signaling in order to join tcra Vα to distal Jα gene segments that define their invariant TCR
(D'Cruz et al., 2010; Rodriguez-Borlado et al., 2003). PTEN (phosphatase and tensin homolog)
is the principal negative regulator of the PI3K pathway. Thymocytes from mice that lack the
microRNA cluster miR-181a1b1 have altered cellular metabolism due to a significant increase in
PTEN expression (Henao-Mejia et al., 2013). Glucose uptake, measured by acquisition of the
fluorescent glucose analog 2-NBDG, and glycolytic rate are reduced in these cells, and nutrient
transporter expression is diminished. As a result of dysregulated PI3K signals, these mice have
deficiencies in DP cells and completely lack NKT cells (Henao-Mejia et al., 2013).

The cytokine interleukin (IL)-7 has a pivotal role in ensuring the survival of developing and
quiescent naïve T cells by increasing expression of the anti-apoptotic factor Bcl-2 (B-cell
lymphoma 2) (Akashi et al., 1997; Maraskovsky et al., 1997; Tan et al., 2001; Yu et al., 2003).
Mice deficient in IL-7 or the IL-7Rα chain have defects in T cell development (Peschon et al.,
1994; von Freeden-Jeffry et al., 1995). IL-7 signals through the JAK3-STAT5 pathway, but can
also activate PI3K (Pallard et al., 1999; Wofford et al., 2008). A recent study suggests that in
addition to maintaining the survival of developing lymphocytes, IL-7 signaling promotes the
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growth and proliferation of DN4 cells by increasing levels of trophic receptors, such as CD71
and the amino acid transporter CD98 (Boudil et al., 2015; Pearson et al., 2012), activities that
previously were attributed mainly to Notch1 signaling. However, Notch1 can induce IL-7Rα
expression and therefore its effects could be downstream of IL-7 signals (Gonzalez-Garcia et al.,
2009; Magri et al., 2009).

Mature naïve T cells exit from the thymus into the periphery. As quiescent cells they primarily
oxidize glucose-derived pyruvate in their mitochondria via oxidative phosphorylation
(OXPHOS), or use fatty acid oxidation (FAO) to generate ATP (Figure 1) (Fox et al., 2005;
Pearce and Pearce, 2013; Pearce et al., 2013; van der Windt and Pearce, 2012; Wang et al.,
2011). A balance between tonic TCR signals and IL-7 are needed to sustain naïve T cells.
Homeostatic proliferation of naïve T cells is supported by TCR ligation with self-peptides
presented on major histocompatibility complex (MHC) molecules in the periphery (Ernst et al.,
1999; Goldrath and Bevan, 1999; Muranski et al., 2000). However, unrestrained Akt activation,
or deletion of negative regulators of TCR stimulation, leads to loss of quiescence (Yang et al.,
2011). T cells defective in tuberous sclerosis complex 1 (TSC1), a negative regulator of mTOR
signaling, prematurely exit from quiescence and have increased rates of apoptosis and
hyperactive responses to TCR stimulation (Yang et al., 2011). In addition, TCR mediated PI3KAkt activation downregulates IL-7Rα (Cekic et al., 2013), but as discussed above, IL-7 signaling
is critically essential to prevent apoptosis and ensure survival of the naïve T cell pool (Rathmell
et al., 2001; Surh and Sprent, 2008). A recent study showed that the metabolite adenosine, which
is a byproduct of metabolic activity, suppresses TCR signaling in a dose dependent manner
(Cekic et al., 2013). The G-protein-coupled adenosine receptor subtype A2AR is predominantly
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expressed in T cells. Binding with adenosine activates cAMP-dependent protein kinase A (PKA),
which suppresses TCR mediated activation of the PI3K pathway and prevents IL-7Rα
downregulation (Cekic et al., 2013).

Activation and effector T cell differentiation

Metabolic reprogramming during T cell activation
Once in the periphery, a mature naïve T cell is like a bomb, lying dormant in the lymphoid
organs and circulation until it is triggered to activate and ‘explode’ in a proliferative chain
reaction. T-cell activation stimulated by TCR ligation and binding with costimulatory molecules
induces metabolic remodeling of the naïve T cell to a program of anabolic growth and biomass
accumulation; this is marked by the engagement of aerobic glycolysis, a process in which
glucose is converted into lactate even though sufficient oxygen is present to support glucose
catabolism via the tricarboxylic acid (TCA) cycle and OXPHOS (Figure 1) (MacIver et al.,
2013; Vander Heiden et al., 2009). Although aerobic glycolysis is less efficient than OXPHOS at
yielding an abundance of ATP per molecule of glucose, aerobic glycolysis can generate
metabolic intermediates important for cell growth and proliferation, and provides a way to
maintain redox balance (NAD+/NADH) in the cell (Figure 2) (Anastasiou et al., 2011;
Macintyre and Rathmell, 2013; Vander Heiden et al., 2009). For example, glucose-6-phosphate
and 3-phosphoglycerate (3PG) produced during glycolysis can be metabolized in the pentose
phosphate and serine biosynthesis pathways, respectively, donating important precursors for
nucleotide and amino acid synthesis (Pearce et al., 2013; Wang et al., 2011). Glucose can also
enter the mitochondria as pyruvate, where it is converted to acetyl-CoA and joins the TCA cycle
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by condensing with oxaloacetate to form citrate. Breakdown of substrates in the TCA cycle not
only provides reducing equivalents for OXPHOS, but also precursors for biosynthesis. Glucosederived citrate can be exported into the cytosol to generate acetyl-CoA by ATP citrate lyase
(ACL) for use in lipid synthesis (Bauer et al., 2005; DeBerardinis et al., 2008; Hatzivassiliou et
al., 2005). Similarly, oxaloacetate can be used to produce aspartate, an additional precursor for
generating nucleotides (Figure 2) (DeBerardinis et al., 2007).

Several transcription factors and signaling pathways coordinately support and regulate this
change in T-cell metabolic programs following activation. Growth factor cytokines such as IL-2
and ligation of costimulatory molecules promote the switch to glycolysis through the
enhancement of nutrient transporter expression and activation of the key metabolic regulator
mTOR (Figure 1) (Frauwirth et al., 2002; Jones and Thompson, 2007; Kolev et al., 2015;
Wieman et al., 2007). Existing as two complexes, mTORC1 and mTORC2, this kinase integrates
extrinsic and intrinsic signals related to nutrient levels, energy status, and stress to induce
changes in cellular metabolism, growth, and proliferation (Laplante and Sabatini, 2012). CD28
ligation enhances PI3K activity, which recruits 3-phosphoinositide-dependent protein kinase-1
(PDPK1) and Akt. PDPK1, together with mTORC2, phosphorylates Akt, which in turn activates
mTORC1. Both Akt and mTOR promote aerobic glycolysis and support effector T-cell
differentiation, growth, and function (Delgoffe et al., 2011; Pollizzi et al., 2015). Akt regulates
nutrient transporter expression and can phosphorylate the glycolytic enzyme hexokinase II,
promoting its localization to the mitochondria and augmenting its enzymatic activity (John et al.,
2011; Miyamoto et al., 2008). mTORC1 activation increases protein translation via
phosphorylation of 4E-BP1 and p70S6 kinase (Laplante and Sabatini, 2012) and promotes lipid
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synthesis by activating SREBP2 (sterol regulatory element-binding protein 2) (Porstmann et al.,
2008).

The upregulation of transcription factors c-Myc, estrogen-related receptor α (ERRα), and
hypoxia inducible factor-1α (HIF-1α) coordinately drive the expression of genes involved in
intermediary metabolism that fuel the rapid proliferation of effector T cells during clonal
expansion (Doedens et al., 2013; Michalek et al., 2011; Wang et al., 2011). First discovered as an
oncogene important for cell growth and proliferation (Cole, 1986; Sheiness et al., 1978), c-Myc
has been shown to be a critical regulator of metabolic reprogramming following T-cell activation
(Wang et al., 2011). c-Myc drives the expression of enzymes that promote aerobic glycolysis and
glutaminolysis and coordinates these metabolic pathways with lipid, amino acid, and nucleic acid
synthesis. However, c-Myc expression is not continually sustained after T-cell activation (Best et
al., 2013; Nie et al., 2012). A recent study suggests that c-Myc induces the transcription factor
AP4, which maintains the glycolytic transcriptional program initiated by c-Myc to support T-cell
population expansion (Chou et al., 2014; Karmaus and Chi, 2014). HIF-1α, a transcription factor
that responds to oxygen levels, also increases glucose uptake and catabolism through glycolysis
(Finlay et al., 2012; Kim et al., 2006). Deletion of its negative regulator, von Hippel-Lindau
(VHL), enhances HIF-1α mediated CD8 T-cell glycolysis and effector responses to persistent
viral infection (Doedens et al., 2013).

ROS signaling
Although much of the attention on metabolic reprogramming in activated T cells has focused on
the engagement of aerobic glycolysis, recent research has revealed the importance of
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mitochondrial-driven activities in this process. In addition to energy production, the electron
transport chain (ETC) is a major source of reactive oxygen species (ROS) (Turrens, 2003), which
are important for T-cell responses (Figure 2) (Chaudhri et al., 1988; Devadas et al., 2002; Jones
et al., 2007). T cells deficient for Rieske iron sulfur protein (RISP), a subunit of mitochondrial
complex III, have impaired activation and antigen-specific T-cell expansion in vitro and in vivo
due to defects in mitochondrial-derived ROS signaling (Sena et al., 2013). More recently, using a
forward genetic screen, another group identified mice with enhanced CD8 T-cell responses to
viral and tumor challenge (Okoye et al., 2015). The source of the heightened immunity gained
after germline mutagenesis was found to be due to the increased expression of an orphan protein,
identified as Lymphocyte Expansion Molecule (LEM). Interestingly, augmented OXPHOS and
mitochondrial ROS levels were detected in CD8 T cells isolated after infection from these mice,
whereas heterozygous LEM-deficient CD8 T cells had reduced OXPHOS and mitochondrial
ROS levels. LEM helps stabilize a protein involved in inserting ETC complex proteins in the
mitochondrial membrane, which may account for the increased ROS and enhanced proliferation
evident in CD8 T cells from these mice (Okoye et al., 2015).

While ROS is produced as a general by-product of mitochondrial metabolism, new studies have
specifically linked the metabolite succinate to both the generation of ROS and activation of HIF1α in settings of inflammation or injury (Chouchani et al., 2014; Tannahill et al., 2013). Innate
immune receptor activation increases intracellular succinate from glutamine via glutaminedependent anerplerosis and the γ-aminobutyric acid shunt pathway and this leads to HIF-1α
stabilization and activation (Tannahill et al., 2013). During ischaemia reperfusion injury, which
happens when blood supply to a tissue is disrupted and then restored, succinate accumulates
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from reverse activity of the enzyme succinate dehydrogenase (SDH) and is rapidly oxidized
upon reperfusion. This leads to over-reduction of the electron carrier coenzyme Q, causing
reverse electron transport through mitochondrial complex I and subsequently, excessive ROS
production (Chouchani et al., 2014; O'Neill, 2014). Given that mitochondrial ROS and HIF-1α
activity are important for the metabolic reprogramming of naïve T cells after activation, it is
interesting to speculate that the metabolite succinate may also support the transition from a naïve
to an activated effector T cell.

Metabolic programming of T helper cell differentiation
Activation of T cells is intimately tied to the engagement of specific metabolic pathways, so it is
no surprise that distinct metabolic programs also support the differentiation of CD4 T helper (Th)
cells into their separate lineages. Initial studies found that suppression of mTOR with rapamycin
promoted the generation of FoxP3+ T regulatory (Treg) cells even in the presence of Th17
polarizing cytokines in vitro (Kopf et al., 2007), and genetic deletion of mTOR in T cells
augmented production of Treg cells upon activation, but not Th1, Th2, or Th17 cells (Delgoffe et
al., 2009). These results are consistent with the metabolic profiles of these cells: Th1, Th2, and
Th17 cells strongly engage glycolysis via mTOR signaling, while Treg cells depend more on the
oxidation of lipids (Figure 1) (Michalek et al., 2011). Th17 cells in particular have been found to
heavily rely on glycolysis for their development and maintenance, stimulated by HIF-1α activity
downstream of mTOR. Mice deficient in HIF-1α have increased generation of Treg cells, and
blocking glycolysis with 2-Deoxy-D-glucose (2-DG) inhibits Th17-cell differentiation (Dang et
al., 2011; Shi et al., 2011). Treg-cell homeostasis and survival depends on the delicate balance
between mTORC1 activation from PI3K-Akt and regulation from PTEN (Huynh et al., 2015;
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Shrestha et al., 2015; Zeng et al., 2013). Signaling through mTORC1 versus mTORC2 also
selectively differentiates CD4 T cells into the Th1 and Th2 lineages, respectively, (Delgoffe et
al., 2011; Lee et al., 2010), although activation of mTORC1 and its component Raptor is still
required for T-cell exit from quiescence to begin the transition into Th2 cells (Yang et al., 2013).
Less is known about T follicular helper (Tfh) cell metabolism compared to other T cell subsets,
but their lineage-defining transcription factor Bcl6, has been shown to suppress glycolysis
potentiated by c-Myc and HIF-1α (Johnston et al., 2009; Nurieva et al., 2009; Oestreich et al.,
2014).

Substrate utilization in activated T cells

Glucose is a key metabolic substrate for T cells. Upon T-cell activation, Glut1 traffics to the cell
surface from intracellular vesicles (Frauwirth et al., 2002; Rathmell et al., 2000; Wieman et al.,
2007). Overexpression of Glut1 in mice results in larger naïve T cells and an increased number
of CD44hi T cells, suggesting that glucose acquisition mediates early steps in T-cell activation,
such as promoting activation marker expression and increasing cell size (Jacobs et al., 2008).
Consistent with these observations, T cell-specific deletion of Glut1 impairs CD4 T-cell
activation, clonal expansion, and survival (Macintyre et al., 2014). When deprived of glucose,
CD8 T cells display defects in functional capacity with reduced IFN-γ, granzyme, and perforin
production (Cham et al., 2008; Cham and Gajewski, 2005; Jacobs et al., 2008). More recently, it
was shown that T cells can become activated and proliferate when glucose catabolism through
aerobic glycolysis is limited as they can rely on OXPHOS (Chang et al., 2013; Sena et al., 2013).
However, in this case, effector function is compromised such that cytokine production is
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impaired due to posttranscriptional regulation by the glycolytic enzyme GAPDH. When
disengaged from glycolysis, GAPDH can function as a RNA-binding protein (RBP) and prevent
the translation of cytokine messenger RNAs containing AU rich elements in their 3’-UTRs
(Chang et al., 2013). Therefore, in addition to providing precursors for biomass, augmenting
aerobic glycolysis in activated T cells allows for the acquisition of full effector function.

Amino acids
While glucose is a critical substrate for T cells, glutamine is also essential during T-cell
activation (Carr et al., 2010; Frauwirth et al., 2002; Wang et al., 2011). T cells increase the
expression of glutamine transporters and their deletion impairs the transition to an effector T cell
(Carr et al., 2010; Sinclair et al., 2013). Clear differences in concentrations of other amino acids
also exist in quiescent compared to activated T cells, corresponding to their distinct metabolic
requirements (Ananieva et al., 2014; Pearson et al., 2012). New research has begun to uncover
the vast array of additional amino acid transporters and catabolizing enzymes that regulate amino
acid levels, revealing previously unappreciated roles for amino acids in T-cell metabolism and
function.

Deficiency in the neutral amino acid transporter Slc7a5 (LAT1), which transports leucine, was
found to prevent the ability of both CD4 and CD8 T cells to metabolically reprogram and
undergo clonal expansion or effector differentiation (Hayashi et al., 2013; Sinclair et al., 2013).
These cells had impaired mTORC1 activation and the inability to induce key metabolic
processes, such as glutamine and glucose uptake (Sinclair et al., 2013). This deficiency,
however, did not impair the ability of CD4 T cells to differentiate into Treg cells. Leucine can

13

activate mTOR via leucyl-tRNA synthetase, and thus it is not surprising that reduced leucine
uptake impairs mTOR activation (Han et al., 2012). However the effects of Slc7a5 deficiency
was more severe than those induced by mTOR inhibition using rapamycin (Sinclair et al., 2013),
suggesting either that rapamycin may not have completely blocked mTOR activation, or that
leucine deficiency has effects over and above limiting mTOR activation (Powell, 2013; Thoreen
et al., 2009). Additionally, it was observed that although no overt decrease in global protein
expression occurred in Slc7a5-deficient cells, protein expression of the key metabolic
transcription factor c-Myc was diminished, despite its increased mRNA expression upon
activation (Sinclair et al., 2013). This raises the intriguing question of whether leucine deficiency
results in posttranslational regulation of c-Myc expression. Alternatively this effect could simply
be due to a limitation in the supply of amino acids in Slc7a5-deficient cells, which is not
sufficient to keep up with the demands of synthesizing proteins such as c-Myc, which have a
short half-life (Sinclair et al., 2013).

Results from another study suggest that modulation of intracellular leucine concentrations can be
used to regulate metabolic reprogramming. It was found that the expression of the cytosolic
branched chain aminotransferase (BCATc), which can reduce intracellular leucine concentrations
through a transamination reaction, limited mTORC1 activation (Ananieva et al., 2014). BCATc
expression was upregulated upon CD4 T-cell activation, and T cells that lacked BCATc had
increased intracellular leucine, which correlated with enhanced activation of mTORC1 and
glycolytic phenotype. Increased BCATc expression has been observed in anergic T cells, which
have impaired metabolic function (Ananieva et al., 2014; Zheng et al., 2009). These data could
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suggest that leucine depletion by BCATc contributes to T-cell anergy through suppression of
mTOR activity.

The alanine serine and cysteine transporter system (ASCT2/Slc1a5), which also transports
glutamine, is another solute carrier whose expression increases following T-cell activation
(Levring et al., 2012). It was recently found that loss of ASCT2 decreased glutamine import and
impaired OXPHOS and glucose metabolism in activated CD4 T cells (Nakaya et al., 2014).
Surprisingly, the loss of ASCT2 did not inhibit proliferation or IL-2 production. However,
ASCT2-deficient cells cultured in vitro had a decreased ability to differentiate into Th1 and Th17
cells, but not Th2 or Treg cells. Interestingly, glutamine transport into cells can substantially
enhance leucine transport via Slc7a5, as increased intracellular glutamine levels result in
glutamine export and concomitant import of leucine by this transporter (Nicklin et al., 2009).
Supporting this additional role for glutamine in T-cell activation, addition of leucine to T cells
lacking ASCT2 helps rescue their polarization defects (Nakaya et al., 2014).

Depletion of extracellular arginine has been found to impair T-cell proliferation and aerobic
glycolysis, but not mitochondrial OXPHOS (Fletcher et al., 2015). However, provided that
extracellular concentrations of citrulline are sufficient, T cells can partially compensate by
synthesizing arginine de novo in an argininosuccinate 1 (ASS1)-dependent process (Fletcher et
al., 2015; Qualls et al., 2012; Tarasenko et al., 2015). One study suggested that ASS1 activity
may contribute to T-cell function in ways beyond simple synthesis of arginine, as deletion of
ASS1 can negatively impact in vitro Th1 and Th17 cell polarization, even in the presence of
extracellular arginine (Tarasenko et al., 2015). Arginine metabolism also has a role in
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macrophage polarization and dictating metabolic phenotype (Galvan-Pena and O'Neill, 2014;
Rath et al., 2014), but whether arginine metabolism also has such roles in T cells remains to be
determined.

A recent study suggests that intracellular recycling of amino acids also contributes to T-cell
amino acid homeostasis. Deficiency in cytosolic protease tripeptidyl peptidase II (TPPII), which
digests proteins for the recycling of amino acids, lead to increased sensitivity to perturbations in
intracellular amino acids concentrations, impaired IFN-γ production, and a susceptibility to viral
infections (Lu et al., 2014). Lack of TPPII activity in both human and murine T cells resulted in
impaired glycolysis due to enhanced degradation of the key glycolytic enzyme hexokinase II, an
effect that likely contributed to their impaired cytokine production (Lu et al., 2014). Another
study also found that TPPII deficiency caused susceptibility to viral infections, although under
these particular experimental conditions, defects in cytokine production were not observed and
the T-cell dysfunction was attributed to premature immunosenescence (Stepensky et al., 2015).
Although it remains to be tested, it may be possible that this premature cell senescence could be
linked to reduced glycolytic flux. In a model of oncogenic stress-induced senescence, inhibition
of hexokinase II or glucose uptake induces senescence in human epithelial cells (Gitenay et al.,
2014).

Many products of amino acid catabolism also have important non-anaplerotic roles that can alter
cell signaling and function. The metabolic byproduct of tryptophan catabolism, kynurenine, can
ligate the aryl hydrocarbon receptor and enhance polarization of CD4 T cells to a Treg
phenotype (Mezrich et al., 2010; Opitz et al., 2011). Another example of this is catabolism of
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phenylalanine by interleukin-4-induced gene 1 protein (IL4I1). When highly expressed by
tumors or APCs, IL4I1 can inhibit T cell proliferation (Boulland et al., 2007; Lasoudris et al.,
2011). This effect appears to be due to the production of H2O2, a product of phenylalanine
catabolism. IL4I1 is also expressed in Th17 and Treg cells (Santarlasci et al., 2012; Scarlata et
al., 2015). The specific purpose for IL4l1 expression in these T-cell subsets remains ambiguous,
although its expression in Th17 cells was speculated to have a self-regulatory role, where its
induction led to diminished proliferation (Santarlasci et al., 2012). However given that low
concentrations of H2O2 can act as a signaling molecule (Veal et al., 2007), IL4I1 might also play
a role in cell signaling pathways independent of mechanisms that inhibit proliferation.

Fluctuations in environmental amino acid concentrations, as well as metabolic products from
amino acid catabolism, can dramatically alter T-cell activity and polarization. A well
documented example of this is indoleamine-2,3-dioxygenase (IDO)-mediated tryptophan
catabolism. IDO, which is often expressed at high levels by antigen presenting cells (APCs) or
tumor cells, can deplete tryptophan within a tissue microenvironment, and this in turn can lead to
inhibition of effector T-cell proliferation and induction of anergy (Munn et al., 2002; Uyttenhove
et al., 2003). Depletion of tryptophan causes activation of the integrated stress response inducer
general control nonderepressible 2 (GCN2) kinase, which results in the inhibition of translation
initiation and metabolic remodeling (Castilho et al., 2014; Guo and Cavener, 2007; Munn et al.,
2005).

Studies into the interactions of APCs with T cells have highlighted multiple pathways through
which APCs modulate extracellular concentrations of amino acids, or their catabolic products, to
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regulate T-cell responses. In a tumor, TGF-β-producing dendritic cells (DCs) can enhance
expression of transporters for histidine, leucine, valine, and tryptophan, depleting these amino
acids from the extracellular microenvironment and directly impairing T-cell proliferation
(Angelini et al., 2002). Treg cells can also enhance expression of particular amino acid
catabolizing enzymes, including arginase 1, histidine decarboxylase, threonine dehydrogenase,
and IL4I1, in skin grafts and bone marrow derived DCs (Cobbold et al., 2009). Limitations in
these amino acids, singularly or in combination, enhanced Treg-cell polarization when T cells
were activated in vitro (Cobbold et al., 2009). Although depletion of amino acids from the
microenvironment appears to be a way in which APCs can negatively regulate T-cell activity, the
converse also occurs, whereby APCs can support T-cell activation through supplementing a
microenvironment. For example, DCs and monocytes can release cysteine, which is thought to
support T-cell activation and function (Angelini et al., 2002; Sido et al., 2000). Cysteine supply
is a limiting factor in T-cell proliferation and is used extensively for protein and glutathione
synthesis, as well as providing beneficial catabolic products, such as taurine, which may support
T-cell function through regulating osmolality (Kaesler et al., 2012; Sikalidis, 2015).

Lipid metabolism
Lipids or fatty acids encompass another critical substrate group for T cells. They are a vital
component of cell membranes, provide a high yielding energy source, and can also supply
substrates for cell signaling and PTMs (Lochner et al., 2015; Thurnher and Gruenbacher, 2015).
Following T-cell activation, the demand for lipids rapidly increases. Within 24 hours, in vitro
activated T cells augment fatty acid synthesis (FAS) while concomitantly decreasing FAO, thus
enhancing the accumulation of fatty acid metabolites needed for membrane synthesis (Wang et
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al., 2011). c-Myc and mTOR have important roles in coordinating these metabolic changes
(Wang et al., 2011; Yang et al., 2013), and SREBP transcription factors are critical for
reprogramming lipid metabolism (Kidani et al., 2013). SREBPs induce expression of genes
involved in FAS and mevalonate pathways, which supply de novo synthesized fatty acids and
cholesterol, respectively (Thurnher and Gruenbacher, 2015). CD4 T cells deficient in Raptor, and
thus mTORC1 signaling, have impaired de novo FAS, most likely due to reduced expression of
SREBP1 and SREBP2 protein (Yang et al., 2013).

Loss of SREBP function in CD8 T cells results in a failure to induce metabolic pathways needed
for clonal expansion during a viral infection (Kidani et al., 2013). Exogenous cholesterol rescues
the defects in SREBP-deficient T cells, suggesting that at least within this context, a lack of
cholesterol is the main limiting factor. This requirement for cholesterol synthesis is consistent
with results which show that perturbing sterol homeostasis in activated T cells – by activating the
liver X receptor (LXR), which targets genes that are involved in cholesterol cellular export –
impairs T-cell proliferation. The inhibitory effect of LXR activation can be overcome through
the addition of mevalonate, a cholesterol precursor (Bensinger et al., 2008). Inhibition of 3hydroxy-3-methylgutaryl-coenzymeA (HMG-CoA) reductase, an enzyme in the mevalonate
pathway, results in a Th2-cell bias in the experimental autoimmune encephalomyelitis (EAE)
disease model, due to impaired biosynthesis of isoprenoids and a subsequent reduction in
prenylation of Ras and RhoA GTPases (Youssef et al., 2002). These data suggest that in addition
to cholesterol homeostasis, other products of the mevalonate pathway can also influence T-cell
differentiation. The impact of commonly used drugs that lower cholesterol by inhibiting HMG-
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CoA reductase can affect both prenylation and cholesterol synthesis, and thus it is plausible these
drugs have multiple effects on activated T cells.

The synthesis of fatty acids is also important for effector T-cell function. Although activated T
cells readily acquire and use extracellular fatty acids, it appears that there may also be cellintrinsic requirements for de novo synthesized fatty acids (Berod et al., 2014; Lee et al., 2014;
O'Sullivan and Pearce, 2014; O'Sullivan et al., 2014). Inhibition of acetyl-CoA carboxylase 1
(ACC1), an enzyme in FAS, was shown to limit Th17-cell differentiation and promote the
development of Treg cells. This effect translated into improved disease outcomes in EAE (Berod
et al., 2014). Inhibition of ACC1 impaired phospholipid synthesis in Th17 cells while also
impairing glycolytic flux, both through aerobic glycolysis and the TCA cycle. In contrast, Treg
cells were able to sustain their requirements for fatty acids through acquisition from extracellular
sources (Berod et al., 2014). ACC1 deficiency also impairs Th1 and Th2 development,
suggesting that CD4 effector T cells have a common requirement for FAS (Berod et al., 2014).
In contrast, T cell-specific deletion of ACC1 does not impair CD8 effector T-cell development
after infection, although effector T-cell expansion is diminished due to increased cell death,
indicating that FAS is required for the persistence of CD8 effector T cells (Lee et al., 2014).
Collectively, these findings suggest that there are varying requirements for de novo synthesized
fatty acids between different T-cell subsets. Interestingly, defects following ACC1 inhibition in
either Th17 cells or CD8 effector T cells can be rescued through the addition of excess free fatty
acids to the media (Berod et al., 2014; Lee et al., 2014), indicating that these cells can
compensate for the lack of FAS if the extracellular fatty acid supply is plentiful. It has also been
observed that addition of extracellular fatty acids can enhance T-cell proliferation (Gorjao et al.,
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2007). It is plausible that the demand for fatty acids is so substantial in these highly proliferative
populations that de novo FAS can be supplemented through extracellular uptake. This concept
would be consistent with a recent study suggesting that lipid released from adipose tissue may
enhance T-cell proliferation in vivo (Kim et al., 2015b). Responses to TNF-mediated signaling in
the hypothalamus induced B- and T-cell proliferation in the spleen, an effect mediated by an
induction of lipolysis through sympathetic nervous system signaling to adipose tissue and a
resultant increase in circulating leptin and free fatty acids (Kim et al., 2015a).

Although in general the balance of FAS to FAO within effector T-cell populations is weighted
heavily towards FAS, effector T cells can utilize FAO (Byersdorfer et al., 2013; O'Sullivan et al.,
2014). Given that the demand for energy is high in these cells, it is likely that they need some
metabolic flexibility in their fuel sources, an idea that is consistent with recent work highlighting
the importance of adenosine monophosphate-activated protein kinase (AMPK) in effector T-cell
function (Blagih et al., 2015). The extent to which FAO occurs in effector T cells is likely to be
highly context dependent, in part due to the heterogeneity of this population of cells during an
immune response. Studies using animal models of graft versus host disease (GvHD) have found
that alloreactive T cells increase fatty acid uptake and enhance FAO compared to other effector
T cells (Byersdorfer et al., 2013; Gatza et al., 2011; Glick et al., 2014). Suppressing Akt during
activation can induce a metabolic profile suggestive of FAO utilization (Crompton et al., 2015),
and culturing CD8 effector T cells in low glucose enhances FAO (O'Sullivan et al., 2014). A
recent report also found that inhibition of T cell signaling through ligation of PD-1 induces
changes in the metabolic profile of activated T cells, including decreased aerobic glycolysis and
enhanced FAO (Patsoukis et al., 2015). Collectively, these data suggest that the utilization of
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FAO in effector T cells may be influenced by a number of factors such as activation state,
exposure to antigen, inflammatory signals, and micro-environmental nutrient availability.

Memory T cell metabolism

Effector T cell populations contract following pathogen clearance and undergo apoptosis, leaving
behind a small population of long-lived memory T cells that can respond vigorously upon
antigen rechallenge (Williams and Bevan, 2007). Although both naïve and memory T cells
acquire effector functions upon activation, memory T cells have an accelerated response to
antigen, proliferate faster, and produce more cytokines than their naïve counterparts. Work from
our laboratory, and others, have shown that changes in metabolism also drive memory T-cell
development (Figure 1) (Araki et al., 2009; Pearce et al., 2009; Rao et al., 2010).

AMPK and mTOR
Increases in intracellular AMP to ATP concentrations activate the energy stress sensor AMPK, a
signal that also promotes FAO (Jones and Thompson, 2007). AMPK is important for the
development of memory T cells and administration of the metabolic stressor and AMPK
activator metformin enhances the generation of memory T cells following infection (Pearce et
al., 2009; Rolf et al., 2013). In addition, AMPK allows for effector T cells to metabolically adapt
during nutrient stress and modulates T-cell effector function through suppression of mTOR
(Blagih et al., 2015; MacIver et al., 2011; Tamas et al., 2006). Inhibiting mTOR with rapamycin
boosts memory T-cell development in vivo (Araki et al., 2009; Pearce et al., 2009; Rao et al.,
2010). Loss of the mTORC1 negative regulator TSC1 compromises formation of memory T-cell
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precursors that are present during the primary effector response (Kaech et al., 2003; Shrestha et
al., 2014). Similarly, suppressing mTORC2 fosters memory T-cell generation (Pollizzi et al.,
2015). Inhibition of mTOR and activation of AMPK also strongly stimulate the catabolic process
of autophagy. Autophagy has been shown to support T-cell viability and bioenergetics after
activation (Hubbard et al., 2010; Pua et al., 2007). Consistent with the idea that activation of
catabolic pathways promotes the development of memory T cells, a recent study found that
deletion of the autophagy molecules Atg5 or Atg7 compromised the formation of CD8 memory
T cells after viral infection (Xu et al., 2014).

FAO and mitochondria
Work from our lab has shown that CD8 memory T cells are dependent on FAO for their
development, long-term persistence, and ability to respond to antigen stimulation (Figure 1)
(Pearce et al., 2009; van der Windt et al., 2012; van der Windt et al., 2013). Enhancing FAO in
memory T cells through increased expression of carnitine palmitoyltransferase 1a (CPT1a) – a
critical mitochondrial transporter of long chain fatty acids and rate limiting step to β-oxidation –
increases CD8 memory T-cell numbers after infection (van der Windt et al., 2012). During an
immune response, common γ chain cytokines like IL-15 and IL-7 have an essential role in
supporting catabolic metabolism by promoting mitochondrial biogenesis, CPT1a expression, and
FAO (van der Windt et al., 2012). As a result, memory T cells have increased mitochondrial
mass and greater spare respiratory capacity (SRC) compared to naïve and effector T cells, which
endows them with a bioenergetic advantage for survival and recall after antigen rechallenge
(Gubser et al., 2013; van der Windt et al., 2012; van der Windt et al., 2013). Interestingly, a
study investigating heterologous prime-boost vaccination found that memory T-cell
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differentiation is hastened and enhanced after secondary or tertiary immunization, including
acquisition of substantially greater mitochondrial mass and SRC (Fraser et al., 2013). In a sense,
memory T cells are metabolically primed and ready to respond to secondary infections. This idea
has recently been extended to innate immune cells under the novel concept of “trained
immunity” whereby metabolic priming confers superior immunity to a secondary pathogenic
insult (Cheng et al., 2014). Previous engagement of aerobic glycolysis in monocytes driven by
mTOR and HIF-1α was found to induce epigenetic modifications that endowed them with
enhanced function against other infections (Cheng et al., 2014).

The specific role of FAO in promoting memory T-cell development and survival remains to be
elucidated, but it appears that metabolic reprogramming associated with FAO enhances
mitochondria-associated processes. Induction of FAO in memory T cells enhances SRC, which is
the reserve capacity of mitochondria to produce energy over and above normal energy outputs
(van der Windt et al., 2012). This parameter is probably important for the longevity of memory
cells, especially in times of stress or nutrient restriction, conditions that may present themselves
when infection is resolved and growth factor signals are scarce. Surprisingly, endothelial cells,
unlike most other cell types, use carbon derived from FAO for nucleotide synthesis and
proliferation (Schoors et al., 2015), providing another way in which FAO supports cell function.

Another unexpected discovery was that memory T cells preferentially use de novo FAS to fuel
FAO (O'Sullivan et al., 2014). Specifically, CD8 memory T cells utilize glucose to produce
triacylglycerides (TAGs) that are subsequently hydrolyzed by lysosomal acid lipase (LAL) to
support mitochondrial FAO (O'Sullivan and Pearce, 2014). It was also recently shown that
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glucose metabolism is critical for CD4 memory T-cell survival, and this is controlled by Notch
signaling (Maekawa et al., 2015). The requirement for FAS in CD8 memory T cells is supported
by a recent study showing that glycerol import into the cell via IL-7-induced aquaporin-mediated
transport is required for memory T-cell longevity (Cui et al., 2015). Glycerol is the molecular
backbone for TAGs. Aquaporin 9 (AQP9)-deficient T cells had reduced glycerol import and
TAG synthesis and impaired memory T-cell survival following viral infection (Cui et al., 2015).

The reasons why CD8 memory T cells synthesize and then catabolize fatty acids in an apparently
futile cycle rather than simply acquire extracellular fatty acids are not understood. However, this
synthesis/catabolism cycle has also been shown to occur in muscle and adipose tissues (Dulloo et
al., 2004; Yu et al., 2002). If viewed on a purely energetic level, this process appears counterproductive, as there would be no net gain in ATP. It is possible that building and burning fatty
acids allows memory T cells to sustain their glycolytic and lipogenic machinery while
maintaining mitochondrial health during times of quiescence, allowing for the rapid recall ability
that is characteristic of memory T cells following antigen recognition and activation (Gubser et
al., 2013; van der Windt et al., 2013). It could also potentially provide a mechanism for
balancing redox state or metabolic intermediates. An energetically futile cycle has been
described in yeast grown in glucose rich media, whereby trehalose cycling provides a buffer
system to maintain intracellular phosphate levels and balance glycolytic intermediates (van
Heerden et al., 2014).
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Emerging topics and concluding remarks

It is an exciting time for the field of immunometabolism. While the body of literature on this
topic is increasing at an exponential rate, much remains to be explored. We are just beginning to
understand the many connections between metabolism and gene regulation in T cells (Kaelin and
McKnight, 2013; Lu and Thompson, 2012; Ost and Pospisilik, 2015; Wang and Green, 2012).
Acetyl-CoA and NAD+ generated from oxidative metabolism are used for histone
acetyltransferase (HAT) and histone deacetylase (HDAC) activity (Canto and Auwerx, 2011;
Imai and Guarente, 2010; Wellen and Thompson, 2012). Protein acetylation is a reversible PTM
that influences epigenetic changes mediated by HATs and HDACs and also controls the actions
of transcription factors and molecular chaperones (Glozak et al., 2005). T-cell metabolic
reprogramming during activation increases cytosolic NAD+ and citrate, the precursor of acetylCoA, which may direct cell-fate decisions through protein acetylation (Berger et al., 1987). In
agreement with this idea, lineage-specific cytokine-encoding genes that affect T-cell
differentiation undergo dynamic changes in histone acetylation after antigen-driven stimulation
(Avni et al., 2002; Fields et al., 2002). The actions of the transcription factor FoxP3 in directing
Treg-cell development are controlled through opposing activities of the HATs p300 and TIP60,
and the HDAC Sirtuin1 (Sirt1) (Beier et al., 2011; Li et al., 2007; Tao et al., 2007; van Loosdregt
et al., 2010). Acetylation also affects the activity of circadian clock proteins, and reciprocally,
the circadian acetylome has been found to regulate the epigenome and mitochondrial metabolic
pathways (Koike et al., 2012; Lu and Thompson, 2012; Masri et al., 2013). Organisms rely on
the cell autonomous transcription–translation oscillator loop managed by solar time to
accommodate physiological changes brought about by the daily pattern of rest, activity, and
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feeding (Curtis et al., 2014). The circadian clock also in part regulates Th17 cell development
(Yu et al., 2013). Circadian rhythm controls nutrient acquisition and metabolic flux and it will be
interesting to see how the body’s internal clock may connect to lymphocyte metabolism,
regulation and function (Rey and Reddy, 2013).

Intermediates from glucose catabolism can be converted into substrates that are needed to
support cell growth and proliferation. Recent studies of one-carbon metabolism in cancer
research involving the serine and glycine biosynthetic pathways may have implications for T-cell
metabolism, given the many common features shared between activated T cells and proliferating
cancer cells. Although the role of one-carbon metabolism in generating units for nucleic acid
synthesis from folate has long been appreciated, more recently it was recognized that this
pathway is an important source of NADPH to maintain redox balance and methyl groups for
methylation (Fan et al., 2014; Locasale, 2013). For example, depletion of methylene
tetrahydrofolate dehydrogenase (MTHFD) in cancer cells results in a decreased cellular
NADPH/NADP+ ratio and increased oxidized glutathione, enhancing sensitivity to oxidative
stress (Fan et al., 2014). Serine and glycine metabolism also have a vital role in cell survival
under harsh environmental conditions of nutrient scarcity and hypoxia (Kim et al., 2015a).
Tumors foster these kinds of conditions, but they are able to survive and function under these
stressors. A recent study found that increased expression of mitochondrial serine
hydroxymethyltransferase (SHMT2) and glycine decarboxylase (GLDC) confer a survival
advantage for glioma cells by allowing them to lower their oxygen consumption and metabolize
toxic molecules in the tumor microenvironment (Kim et al., 2015a). T cells also migrate and
travel to sites of infection or tumors and must adapt to these hypoxic or nutrient-depleted
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environments (Pearce et al., 2013). It remains to be explored whether these metabolic pathways
support lymphocyte survival by similar mechanisms or have evolved to serve other purposes.

Another area of interest is how substrate availability affects T-cell differentiation and their
functional fate. Studies investigating the relationship between the gut microbiome and
lymphocytes have found that metabolites produced by commensal bacteria have important
implications for maintaining immune cell gastrointestinal homeostasis and defense against
pathogens. Short chain fatty acids (SCFA) such as butyrate, acetate, and propionate produced by
bacteria induce differentiation of colonic Treg cells (Furusawa et al., 2013; Smith et al., 2013)
and also Th17 cells under certain conditions (Park et al., 2015). The vitamin A metabolite
retinoic acid can synergize with TGF-β to stimulate Treg conversion (Coombes et al., 2007;
Denning et al., 2007; Elias et al., 2008; Mucida et al., 2007; Sun et al., 2007). However, vitamin
A metabolite deficiency also abrogates Th1 and Th17 cell immunity (Hall et al., 2011) and, more
recently, was found to diminish type 3 innate lymphoid cells (ILC3s), but expand ILC2 cells
(Spencer et al., 2014). Lymphocytes can also regulate whole body metabolism by affecting the
tissues in which they reside. ILC2s can promote ‘beiging’ of white adipose tissue and therefore
control caloric expenditure through secretion of methionine-enkephaline peptides (Brestoff et al.,
2015). Loss of insulin sensitivity due to inflammation of adipose tissue in obesity and type 2
diabetes results in part from deficiencies in adipose tissue-specific Treg cell populations
controlled by the transcriptional regulator PPAR-γ (Cipolletta et al., 2012; Feuerer et al., 2009).
These are just a few examples of what remains to be explored in the interplay between
lymphocytes, their environment, and metabolism.
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In the development of novel therapeutics for the treatment of human disease, targeting T-cell
metabolism provides a unique opportunity to manipulate T-cell function (O'Sullivan and Pearce,
2015). For example, it has been demonstrated that compared to Th1 and Treg cells, Th17 cells
have elevated pyruvate dehydrogenase kinase 1 (PDK1) expression, which promotes aerobic
glycolysis through inhibition of pyruvate dehydrogenase (PDH). Inhibition of PDK1 using
dichloroacetate (DCA) selectively impairs Th17 proliferation and survival and reduces T-cell
mediated inflammation in models of inflammatory bowel disease and EAE (Gerriets et al.,
2015). Targeting trophic transporters on T cells may also provide a way in which to manipulate
T-cell function through altering their nutrient uptake; for example JPH203, which inhibits amino
acid transporter Slc7a5, could be used to inhibit inflammatory T cells without impairing Tregcell function (Hayashi et al., 2013; Sinclair et al., 2013). In the context of cancer, the
development of adoptive cellular immunotherapies using in vitro expanded tumor infiltrating
lymphocytes (TILs) could benefit from tailoring culture conditions to optimize TIL metabolism
prior to transfer into the patient (Restifo et al., 2012). Exaggerated glycolysis and cell size
resulting from in vitro expansion conditions, such as high glucose, can be detrimental to TIL
survival and persistence in vivo. Strategies to limit glycolysis directly or suppress Akt activation
in TILs have already shown promising results in this context (Crompton et al., 2015; Sukumar et
al., 2013). Inhibiting glycolysis and oxidative metabolism with 2-DG and metformin may also
hold therapeutic potential in other disease settings as highlighted by a recent study using models
of system lupus erythematosus (Yin et al., 2015).

It is apparent that many diverse processes integrate with lymphocyte signaling, gene regulation,
and function to shape T-cell metabolism. Understanding the metabolic regulation that dictates T-
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cell fate and how nutrient availability and micro-environmental factors influence T-cell function
will provide further insight into immune cell biology and could lead to new approaches to
treating human diseases.
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Figure 1. Metabolism drives the life cycle of T cells.
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T cells engage specific metabolic pathways during the course of their development that underpin
their differentiation and function. Naïve T cells mature and exit from the thymus primarily
relying on OXPHOS for their metabolic needs, although they augment glycolytic metabolism
during times of proliferation that follow TCR gene rearrangements. In secondary lymphoid
organs, TCR ligation, costimulation, and growth factor cytokine signals induce clonal expansion
and metabolic reprogramming of an antigen-specific T cell. This conversion to an activated
effector T cell is marked by the engagement of aerobic glycolysis and increased OXPHOS
activity. Glycolytic metabolism differentiates CD4 Th1, Th2, and Th17 effector cells (and
possibly Tfh cells) from Treg cells. Promoting FAO and catabolic metabolism enhances Treg
and memory T cell development (blue arrow). Memory T cells are a quiescent population of cells
that primarily use OXPHOS, but both OXPHOS and glycolysis increase rapidly after antigen
rechallenge and facilitate their recall responses.
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Figure 2. Metabolic pathways that support T cells.
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ATP is the molecular currency of energy in the cell. It can be derived from glucose through two
integrated pathways. The first of these, glycolysis (green), involves the enzymatic breakdown of
glucose to pyruvate in the cytoplasm. The TCA cycle (orange) encompasses the second pathway
where pyruvate is converted to acetyl-CoA in the mitochondria and shuttled through several
enzymatic reactions to generate reducing equivalents to fuel OXPHOS (brown). Other substrates
can also be metabolized in the TCA cycle, such as glutamine via glutaminolysis (purple) or fatty
acids via β-oxidation (FAO) (gray). These connected biochemical pathways can also provide
metabolic precursors for biosynthesis. Intermediates from glucose catabolism during glycolysis
can shuttle through the pentose phosphate (dark blue) and serine biosynthesis pathways (red) to
fuel nucleotide and amino acid production. Oxaloacetate from the TCA cycle can similarly be
used to generate aspartate for use in nucleotide synthesis. Precursors for amino acid and
nucleotide biosynthesis can be obtained from glutamine. Citrate from the TCA cycle can be
exported from the mitochondria and converted to acetyl-CoA for FAS (light blue). ROS
generated from the ETC during OXPHOS can also act as secondary signaling molecules.
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Abstract

Choices. Choices have consequences. Immune cells survey and migrate throughout the body and
sometimes take residence in niche environments with distinct communities of cells, extracellular
matrix, and nutrients that may differ from those in which they matured. Imbedded in immune
cell physiology are metabolic pathways and metabolites that not only provide energy and
substrates for growth and survival, but also instruct effector functions, differentiation, and gene
expression. This review of immunometabolism will reference the most recent literature to cover
the choices that environments impose on the metabolism and function of immune cells and
highlight their consequences during homeostasis and disease.

Introduction

Cells of the immune system possess particular sets of skills – skills that are vital for host defense
and tissue homeostasis, but also cause disease if not properly controlled – skills that make them
altogether fairly peculiar. Unlike other cells in the body, immune cells possess the ability to
respond to environmental signals and assume a wide variety of distinct functional fates. Immune
cells can morph from dormant sentinels into pathogen killing machines, migrate from one tissue
to another, modulate surface receptor expression, clonally expand, secrete copious amounts of
effector molecules, or exert controlling effects over neighboring cells. After the burst of activity
following an immune response, these specialized cells can die, creating space and limiting tissue
damage in a particular environment, or return to resting states that allow them to persist for
extended periods of time in readiness for a secondary response.
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The activation, expansion, engagement of effector functions, and return to homeostasis of
immune cells are intimately linked and dependent on dynamic changes in cellular metabolism.
The utilization of particular metabolic pathways is controlled on one level by growth factors and
nutrient availability dictated by competition between other interacting cells, and on another level
by the exquisite balance of internal metabolites, reactive oxygen species (ROS), and reductive
and oxidizing substrates. Studying immune cells, particularly lymphocytes and myeloid cells, has
lent deep insight into how cells differentiate and coordinate their behaviors with metabolism
under a wide array of settings.

Leukocytes are also nomads and settlers. They migrate from the place where they develop to
survey the entire body, and sometimes take up residence in tissues in which they did not
originate. In doing so, they must adapt to an ecosystem comprised of unique cells, extracellular
matrix, growth factors, oxygen, nutrients, and metabolites. How do they do this and what are the
genetic, metabolic, and immunological consequences of these adaptations? In this review, we
will explore the interactions between immune cells and the tissue environments they inhabit, how
these impinge on their metabolism, how their metabolism instructs their function and fate, and
how these relationships contribute to tissue homeostasis and disease pathology. The central
concepts of immune cell metabolism have been covered extensively in several reviews (Buck et
al., 2015; MacIver et al., 2013; O'Neill and Pearce, 2016; O'Neill et al., 2016; Pearce et al.,
2013), and thus will not be discussed at length here.
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The tumor microenvironment

Recent breakthroughs in immunotherapy have shown that eliciting immune responses against
multiple types of cancer can lead to considerably longer-lasting remissions, or in some cases
complete regression of metastatic disease (Ribas, 2015). Although it is well known that cancer
cells can evade immune recognition through “immunoediting”, the process by which antitumor
immune responses, especially those from tumor infiltrating T lymphocytes (TILs), select for
cancer cell clones that no longer express detectable tumor antigens (Vesely and Schreiber, 2013),
the advent of effective cancer immunotherapies has shown that additional mechanisms of
immunosuppression exist that limit or impair antitumor immunity. Thus, considerable efforts are
underway to elucidate other mechanisms that restrain antitumor responses to develop new and
more efficacious forms of immunotherapy.

At the forefront of these mechanisms to consider is how immune cell metabolism, and thus
immune cell function, is altered by the tumor microenvironment. Tumors are a major disturbance
to tissue homeostasis, creating metabolically demanding environments that encroach on the
metabolism and function of infiltrating immune and stromal cells. The unrestrained cell growth
seen in cancer is often supported by aerobic glycolysis, the same metabolic pathway needed to
fuel optimal effector functions in many immune cells (Pearce et al., 2013; Warburg, 1956;
Warburg et al., 1958). At minimum, this similarity creates a competition for substrates between
tumors and immune cells. The demand for nutrients, essential metabolites, and oxygen imposed
by proliferative cancer cells, in combination with their immunosuppressive by-products, creates
harsh environmental conditions in which immune cells must navigate and adapt (Figure 3). How
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tumor and immune cells share or compete for resources in this environment, and how such
relationships regulate antitumor immunity are important questions to address.

Hypoxia
When tumor growth exceeds the vasculature’s ability to fully perfuse the tumor
microenvironment with oxygen, regions of hypoxia are established and induction of the hypoxiaresponsive transcription factor HIF-1α intensifies cancer cell glucose utilization and lactate
release (Eales et al., 2016). Using 13C-labeled glucose, Hensley and colleagues traced the fate of
glucose within healthy lung tissue and tumors of patients with non-small lung cell carcinoma and
found that even within a single tumor, heterogeneity in glucose utilization exists (Hensley et al.,
2016). Lesser-perfused regions of the lung tumors were associated with higher glucose
metabolism whereas higher-perfused regions could utilize circulating lactate, transported through
monocarboxylate transporter 1 (MCT1), as an alternative TCA cycle substrate (Sonveaux et al.,
2008). Lactate metabolism in oxygenated cancer cells also increases glutaminolysis (PérezEscuredo et al., 2015). How this metabolic heterogeneity in tumor cells relates to intratumoral
immune cell function has not been well elucidated, but exposure of NK and T cells to high
concentrations of lactate impairs their activation of the transcription factor NFAT and production
of the cytokine IFN-γ (Brand et al., 2016). Lactic acid also disrupts T cell motility and causes
loss of cytolytic function in CD8 T cells (Haas et al., 2015). Moreover, decreasing conversion of
pyruvate to lactate by genetic targeting of lactate dehydrogenase A (LDHA) in tumors helps to
restore T cell infiltration and function (Brand et al., 2016), linking lactate production to
immunosuppression observed in the tumor microenvironment (Figure 3).
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Lactate uptake by tumor-associated macrophages (TAMs) also stimulates tumor progression by
inducing vascular endothelial growth factor (VEGF) and arginase I (Arg1) expression through
HIF-1α (Colegio et al., 2014). Moreover, chronic VEGF signaling in hypoxic areas leads to
elevated glycolysis in endothelial cells, resulting in excessive endothelial sprouting and abnormal
leaky vasculature (Goveia et al., 2014). Interestingly, inhibition of REDD1, a hypoxia-induced
inhibitor of mTOR, in TAMs increases their rates of glycolysis to a level that competes with
neighboring endothelial cells for glucose and suppresses their angiogenic activity. This metabolic
tug-of-war over glucose helps restore vascular integrity, improve oxygenation within the tumor,
and prevent metastases (Wenes et al., 2016), providing an example of an intimate metabolic
relationship that exists between cells in tumors.

Hypoxia also has considerable effects on TIL function, proliferation, and migration (Vuillefroy
de Silly et al., 2016). Increases in HIF-1α activity by culturing T cells in physiologic normoxia
(~3-5% O2), genetic deletion of von Hippel-Lindau (VHL) factor, or inhibiting activity of the
oxygen-sensing prolyl-hydroxylase (PHD) family of proteins, enhances CD8 T cell glycolysis
and effector functions and promotes antitumor immunity (Clever et al., 2016; Doedens et al.,
2013; Finlay et al., 2012; Wang et al., 2011). HIF-1α is also needed for the production of the
metabolite S-2-hydroxyglutarate (S-2HG), which can drive epigenetic remodeling in activated
CD8 T cells and enhance IL-2 production and antitumor defenses (Tyrakis et al., 2016).

Thus, one may expect that hypoxia would potentiate HIF-1α activity and TIL effector functions
in tumors, however this is not what is observed. In addition to signals received from TIL IFN-γ
(Noman et al., 2014), HIF-1α also induces the expression of the suppressive ligand PD-L1 in
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tumor cells, TAMs, and myeloid-derived suppressor cells (MDSCs), and this can lead to TIL
suppression via PD-1 (Figure 3). Moreover, recent work in both mouse and human tumors
showed that CD8 TILs lose mitochondrial mass, membrane potential, and oxidative capacity,
particularly within the most dysfunctional PD-1+ CD8 T cells (Scharping et al., 2016). The loss
of mitochondrial function in TILs correlated with diminished expression of PPAR-gamma
coactivator 1α (PGC1α) over time and a block in their proliferation and IFN-γ production.
Perhaps severe hypoxia ultimately diminishes TIL effector functions. Indeed, respiratory
supplementation of oxygen or treatment with metformin decreased intratumoral hypoxia and
relieved several immunosuppressive features in the tumor microenvironment; the latter also
served as an adjunct therapy that enhanced the antitumor effects of PD-1 blockade (Hatfield et
al., 2015; Scharping et al., 2017). These findings suggest that remodeling the hypoxic tone in
tumors may be an essential component to developing more efficacious forms of immunotherapy
for patients.

Nutrient alterations and competition within the tumor microenvironment
Apart from hypoxia, the competition for nutrients and metabolites between tumor cells and
infiltrating immune and stromal cells can be fierce, consequently influencing signal transduction,
gene expression, and the metabolic activities of these neighboring cells. For example, tumor cells
manipulate surrounding adipocytes to increase lipolysis to whet their appetite for fatty acids
(Nieman et al., 2011). Cancer associated fibroblasts degrade tryptophan that not only starves
immune cells in the local environment of an essential amino acid, but also leads to the
production of the immunosuppressive metabolite kynurenine (Hsu et al., 2016). Moreover,
glucose is a critical substrate for the antitumor functions of effector T cells and M1 macrophages,
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which both require engagement of aerobic glycolysis for their activation and full effector
functions (Buck et al., 2015; O'Neill and Pearce, 2016). Augmented aerobic glycolysis in cancer
cells and endothelial cells places immune cells and their neighbors at odds (Figure 3). Glucose
deprivation represses Ca2+ signaling, IFN-γ production, cytotoxicity, and motility in T cells and
pro-inflammatory functions in macrophages (Cham et al., 2008; Chang et al., 2013; Chang et al.,
2015; Macintyre et al., 2014). Several recent studies have demonstrated that the glycolytic
activities of cancer cells may restrict glucose utilization by TILs, thereby impairing antitumor
immunity (Chang et al., 2015; Ho et al., 2015; Zhao et al., 2015). Increasing glycolysis rates of
tumor cells through overexpression of the glycolytic enzyme hexokinase 2 (HK2) suppressed
glucose-uptake and IFN-γ production in TILs and created more immunoevasive tumors (Chang
et al., 2015; Ho et al., 2015). Zhao and colleagues found that glucose restriction imposed by
ovarian cancer leaves microRNA repression of the methyltransferase EZH2 intact in CD8 T
cells, reducing their survival and functional capacity (Zhao et al., 2015). Thus, tumor cells can
selfishly coerce or outcompete neighboring cells for glucose to supply their own metabolic
demands in a manner that simultaneously suppresses immune defenses.

Amino acid deprivation in the tumor microenvironment serves as another metabolic checkpoint
regulating antitumor immunity. Glutaminolysis in tumor cells is critical to replenish metabolites
through anaplerotic reactions, which could result in competition for glutamine between tumor
cells and TILs (Jin et al., 2015; Pérez-Escuredo et al., 2015). Glutamine controls mTOR
activation in T cells and macrophages and is also a key substrate for protein O-GlcNAcylation
and synthesis of S-2HG that regulate effector T cell function and differentiation (Sinclair et al.,
2013; Swamy et al., 2016; Tyrakis et al., 2016). TAMs, MDSCs, and tolerizing dendritic cells
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(DCs) can suppress TILs through expression of essential amino acid (EAA)-degrading enzymes
such as Arg1 and indoleamine-2,3-dioxygenase (IDO) (Figure 3) (Lee et al., 2002; Munn et al.,
2002; Rodriguez, 2004; Uyttenhove et al., 2003). Indeed, inhibitors of Arg1 and IDO are under
investigation as therapeutic targets in clinical trials (Adams et al., 2015). Several recent studies
have highlighted the critical roles of other amino acids such as arginine, serine, and glycine in
driving T cell expansion and antitumor activity, but how the availability of these fluctuate within
the tumor microenvironment is not clear (Geiger et al., 2016; Ma et al., 2017). Currently, a
knowledge gap exists of how the availability of various nutrients and metabolites vary across
tumor types, genotypes or even spatially within tumors to affect antitumor immune responses.

Bioactive lipids, modified lipoproteins, and cholesterol metabolism within the tumor are also
important mediators of immune cell function. Like macrophages in atherosclerotic plaques, DCs
in the tumor can accumulate oxidized lipoproteins through scavenger receptor mediated
internalization and formation of lipid droplets, which can ultimately impair their ability to crosspresent tumor antigens and activate T cells (Cubillos-Ruiz et al., 2015; Ramakrishnan et al.,
2014). Expression of lectin-type oxidized LDL receptor 1 (LOX-1) selectively marks MDSCs
and oxidized lipid uptake and lipoprotein metabolism contributes to their T cell suppressive
functions (Condamine et al., 2016). In addition, blocking cholesterol esterification in TILs by
targeting ACAT1 pharmacologically or genetically increases intracellular levels of cholesterol
and confers superior T cell responses in a model of melanoma (Yang et al., 2016). It is possible
that as immune cells adapt to different tumor microenvironments and the limited availability of
“immune stimulatory” nutrients, they become more dependent on alternative fuel sources (such
as fats or lactate) that are less conducive to supporting antitumor effector functions. In summary,
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more elaborate knowledge of these forms of metabolic cross talk or competition between cells
within tumors is needed before one can begin to think about how to manipulate these
relationships in a manner that alters tumor progression.

Metabolic exhaustion in TILs and checkpoint blockade
As TILs adapt to the tumor microenvironment, they progressively lose their ability to respond to
T cell receptor (TCR) stimuli, produce effector cytokines, and proliferate – a process termed
functional exhaustion or hyporesponsiveness. This is in part due to the upregulation of several
inhibitory receptors like PD-1, LAG3, TIGIT, and CTLA-4 that desensitize T cells to tumor
antigens (Wherry and Kurachi, 2015) (Figure 3). PD-1, its ligand PD-L1, and CTLA-4 are
important checkpoints for T cells in tumors and the targets of a new and powerful class of cancer
treatments that elicit effective and durable responses in patients across multiple cancer types
(Ribas, 2015). Interestingly, both chronic exposure to antigen or environmental triggers such as
glucose deprivation can upregulate PD-1 (Chang et al., 2013; Wherry and Kurachi, 2015). PD-1
not only suppresses TCR, PI3K and mTOR signaling in T cells, but also dampens glycolysis and
promotes fatty acid oxidation (FAO) – features that may enhance the accumulation of
suppressive regulatory CD4 T (Treg) cells in tumors (Bengsch et al., 2016; Parry et al., 2005;
Patsoukis et al., 2015). Indeed, blockade of PD-1 re-energizes anabolic metabolism and
glycolysis in exhausted T cells in an mTORC1 dependent manner (Chang et al., 2015; Staron et
al., 2014). This breathes caution into the types of drug combinations one may consider with αPD-1:PD-L1 blockade or other forms of immunotherapy. Metabolic interventions, such as the
use of mTOR inhibitors, must be targeted specifically to avoid unintended compromises of
immune cell function. The PD-1:PD-L1 axis may also directly affect the metabolic activity of
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tumor cells (Figure 3). It was shown that PD-L1 expression correlated with the rates of
glycolysis and the expression of glycolytic enzymes in those cells (Chang et al., 2015).
Furthermore, checkpoint blockade antibodies including α-PD-L1 led to an increase in
extracellular glucose in tumors in vivo that likely contributed to the improved TIL function and
subsequent tumor regression observed. On this note, tumor cell-intrinsic PD-1 expression has
also been observed that counter intuitively may increase intrinsic mTOR signaling and tumor
growth (Kleffel et al., 2015). Collectively, these findings suggest there may be broader role of
the PD-1:PD-L1 axis in cellular metabolism that extends beyond T cells.

Improving the proportion of patients that respond to immunotherapy is an intense area of study,
ranging from the search for biomarkers of response, target discovery, to testing new combination
therapies. Likely, the most effective therapies will coordinately target co-inhibitory receptor to
ligand interactions and restore a T cells’ ability to utilize metabolic substrates necessary to
sustain their effector functions. Seemingly paradoxical is the observation that dampening
effector T cell differentiation by impairing glycolysis and boosting mitochondrial FAO and
OXPHOS potentiates their survival and functional capacity (Buck et al., 2016; Sukumar et al.,
2013). Additionally, manipulating metabolic enzyme expression to help T cells adapt to
metabolic perturbations in the tumor microenvironment may be other viable strategies (Clever et
al., 2016; Doedens et al., 2013; Ho et al., 2015; Scharping et al., 2016), especially for adoptive
cell therapy, a personalized form of cancer treatment that allows for the manipulation and
expansion of a patient’s antitumor T cells prior to re-infusion (O'Sullivan and Pearce, 2015). As
our capability to selectively reprogram T cell metabolism and reinvigorate tumor-specific T cells
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improves, there is much promise to provide greater therapeutic benefits to more patients,
especially to those with previously incurable cancers.
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Figure 3. Metabolic tug-of-war within the tumor microenvironment.
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The balance of nutrients and oxygen within the tumor microenvironment controls immune cell
function. Glucose and amino acid consumption by tumor cells can outpace that of infiltrating
immune cells, specifically depriving them of nutrients to fuel their effector function. Poorly
perfused tumor regions drive hypoxia response programs in tumor cells, macrophages, and T
cells. Increased HIF-1α activity in response to hypoxia or other mechanisms promotes glycolysis
and increases concentrations of suppressive metabolites and acidification of the local
environment. As a by-product of glycolysis, lactate concentration increases, which is
coordinately utilized by tumor cells to fuel their metabolism, promotes macrophage polarization,
and directly suppresses T cell function. The ability of T cells to target tumors is further limited
by their upregulation of co-inhibitory receptors and engagement with their ligands on
neighboring tumor cells and macrophages. As T cells progressively enter a dysfunctional state,
their mitochondrial mass and oxidative capacity declines ultimately leading to their failure to
meet bioenergetic demands to sustain effector functions and control tumor cell growth.
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The gut environment

While the tumor microenvironment is often depicted as nutrient restrictive, the mammalian
gastrointestinal tract represents a metabolically rich and diverse tissue system. Its primary
function is to digest and absorb nutrients with the aid of microbial species contained within the
lumen. A single layer of epithelial cells is all that separates these commensal microbes from the
rest of the body. The majority of intestinal epithelial cells (IECs) are absorptive enterocytes that
digest and transfer nutrients, however additional specialized epithelial lineages exist with a
diverse array of functions. For example, goblet and Paneth cells secrete mucins and antimicrobial
peptides that fortify the barrier against potentially pathogenic microbes, microfold (M) and
goblet cells assist in the transferring of luminal antigens across the epithelial barrier for sampling
by mucosal DCs, and Tuft cells are important for sensing and responding to protozoa and
helminths. Together with intestinal resident immune cells including innate lymphoid cells
(ILCs), intraepithelial lymphocytes (IELs), helper T cells and B cells, a balancing act between
barrier protection and microbial tolerance with surveillance and inflammation is maintained
(Figure 4). While the relationship between gut commensal microbes and immune cell
development and function and also how IECs interface with immune system regulation has
recently been reviewed (Kurashima and Kiyono, 2017), we examine the unique constraints that
this environment presents on cellular immunometabolism.

While IECs control the intake of nutrients from the luminal environment of the gut, a recent
study provides evidence that the way they are structured and uniquely placed controls their
metabolic activity and function (Kaiko et al., 2016). The layer of epithelia in the small intestine
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are organized into crypts and villi, which form invaginations that serve to optimize surface area
whereby nutrients can be absorbed. At the base of the colonic crypt lie epithelial stem/progenitor
cells that differentiate into specialized IECs as they migrate up the crypt-villus axis until they are
eventually lost from the epithelial layer. This process of self-renewal from the crypt is
continuous and therefore is a site of active proliferation (Kurashima and Kiyono, 2017). Kaiko,
Ryu and colleagues screened microbiota derived products for their impact on intestinal epithelial
progenitors and identified the short chain fatty acid (SCFA) butyrate as a potent inhibitor of
intestinal stem cell proliferation at physiologic concentrations present within the lumen (Kaiko et
al., 2016). They further found that differentiated colonocytes located at the forefront of the villi
metabolized butyrate to fuel OXPHOS, thereby limiting its access to underlying progenitor cells,
which do not readily utilize this substrate. Either removal of the ability to metabolize butyrate via
deletion of acyl-CoA dehydrogenase or increased abundance of butyrate prevented the rapid
regeneration of epithelial tissue after gut injury. Thus a combination of physical separation in the
crypt and fermentation of butyrate by mature colonocytes protects the proliferating progenitor
pool of IECs (Figure 4).

B and Tfh cell metabolism
Another unique structural feature of the gut are the Peyer’s patches, aggregates of gut associated
lymphoid tissue (Reboldi and Cyster, 2016). Found in the small intestine, they represent a
specialized lymphoid compartment continuously exposed to food- and microbiome-derived
antigens. Due to this exposure, Peyer’s patches are rich in germinal centers (GCs), which are
comprised of B, T, stromal, and follicular DCs. B cells segregate into zones where they undergo
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cycles of proliferation and differentiation and compete for signals directing class switch
recombination (CSR) and survival from T follicular helper (Tfh) cells, allowing further
maturation of the antibody repertoire.

Although the literature on B and Tfh cell metabolism is still developing, it has been shown that B
cell activation induced by either α-IgM ligation or LPS increases Glut1 expression and glucose
uptake downstream of PI3K and mTOR signaling (Caro-Maldonado et al., 2014; Doughty et al.,
2006; Jellusova and Rickert, 2016; Lee et al., 2013; Woodland et al., 2008). Glycolysis and
OXPHOS are augmented as well as mitochondrial mass (Caro-Maldonado et al., 2014; Doughty
et al., 2006; Dufort et al., 2007). Increased glucose acquisition also fuels de novo lipogenesis
necessary for B cell proliferation and growth of their intracellular membranes. Inhibition of the
fatty acid synthesis (FAS) enzyme ATP-citrate lyase in splenic B cells results in reduced
expansion and expression of plasma cell differentiation markers (Dufort et al., 2014). Although
apoptosis inducing factor (AIF) is required for T cell survival via electron transport chain (ETC)
complex I function and respiration, AIF deficiency in B cells has no impact on their development
or survival because of their reliance on glucose metabolism (Milasta et al., 2016). B cells
cultured in galactose fail to expand unlike T cells, which can activate and proliferate in the
presence of either galactose or glucose (Chang et al., 2013; Milasta et al., 2016). On the other
hand, the transition to durable humoral immunity by long-lived plasma cells (LLPCs) was shown
to be dependent on mitochondrial pyruvate import (Figure 4). Glucose supports antibody
glycosylation, but LLPCs acquire more glucose than their short-lived counterparts and their
long-term survival is dependent on their ability to siphon glucose-derived pyruvate into the
mitochondria during times of metabolic stress (Lam et al., 2016).
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It is interesting to speculate that with the constant proliferation of GC B cells in the gut and the
importance of glucose and glycolysis in activated plasma cells, access to glucose would become
limiting for other cells that occupy this microniche. A few studies suggest that Tfh cells have
evolved to be uniquely suited to survive under these constraints. It has been shown that Tfh cells
have less mTORC1 activation and reduced glycolysis compared to Th1 cells (Ray et al., 2015).
In part, this may be due to expression of their lineage defining transcription factor Bcl6, which
can suppress glycolysis potentiated by c-Myc and HIF-1α (Johnston et al., 2009; Nurieva et al.,
2009; Oestreich et al., 2014). Consistent with this, overexpression of Bcl6 reduces glycolysis in
T cells, and ablation of mTOR using shRNA favors Tfh cell development over Th1 cells in vivo
after viral infection (Ray et al., 2015) (Figure 4). However, a more recent study using mice with
conditional deletions of mTORC1 and mTORC2 via OX40 and CD4 cre recombinase observed a
requirement of mTOR signaling in Tfh cell development and GC formation within Peyer’s
patches (Zeng et al., 2016). The former applied retroviral mTOR shRNA, which requires T cells
be fully activated prior to knockdown, while this more recent report used mice where mTOR was
excised during T cell development or at the moment of T cell activation, which may explain the
disparity between the studies.

In addition to possibly limiting quantities of glucose substrate within GCs, these microniches
contain areas of hypoxia, resulting in HIF-1α activation (Abbott et al., 2016; Cho et al., 2016). B
cells placed under hypoxic conditions had reduced activation induced deaminase expression and
subsequently underwent less CSR to the pro-inflammatory IgG2c isotype when cultured in
conditions that promote IgG production (Cho et al., 2016). In contrast, B cells cultured in IgA-
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promoting conditions during hypoxia were unaffected, yielding comparable levels of IgA to cells
kept at normoxia and highlighting how lymphocyte function may be fine-tuned to varying
oxygen tension in tissues (Figure 4). B cells isolated from mice with constitutive activation of
HIF-1α by deletion of its suppressor VHL had defects in IgG2c production, which was attributed
to diminished mTORC1 activation. B cells from Raptor deficient heterozygotes also yielded
fewer IgG antibodies (Cho et al., 2016). A separate study found that the mTOR inhibitor
rapamycin dampens CSR, yielding the formation of lower affinity, more cross reactive B cell
antibodies, which offered broad protection against heterosubtypic flu infection (Keating et al.,
2013). Both mTORC1 and HIF-1α promote aerobic glycolysis (O'Neill and Pearce, 2016).
However, the metabolic activities of the cells cultured under different isotype conditions while
under hypoxia were not explored. Cytokines initiate CSR to distinct isotypes and signals derived
from these growth factors might be responsible for the differences in metabolic signaling and
suggest varying requirements to initiate metabolic programs and CSR in B cells. Secretion of
IgA predominates the gut and is critical to maintaining barrier protection and bacterial
homeostasis (Kurashima and Kiyono, 2017). The apparent stability of CSR to the IgA isotype
under hypoxia and impaired pro-inflammatory IgG2c subtype might have evolved to ensure
tolerance with the microbiome, while concurrently providing a stringent method of selection of
antibodies produced during inflammatory responses to pathogen-derived antigens.

Nutrients and immune signals in the gut
The metabolic relationship between commensals and immune cells in the gut is further illustrated
by the finding that SCFAs derived from the fermentation of dietary fiber by gut microbiota
promote B cell metabolism and boost antibody responses in both mouse and human B cells (Kim
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et al., 2016). Supplementation with dietary fiber or the SCFAs acetate, propionate, and butyrate
increases intestinal IgA production, as well as systemic IgG during infection (Figure 4).
Culturing B cells with SCFAs was shown to raise acetyl-CoA levels and increase mitochondrial
mass, lipid content, and FAS leading to increased plasma cell differentiation and metabolic
activity (Kim et al., 2016). Part of this phenotype could be attributed to histone deacetylase
(HDAC) inhibition, an established effect of SCFA supplementation.

In addition to their effects on B Cells, SCFAs have been found to promote the development and
function of colonic Treg cells via induction of Foxp3 in a HDAC dependent manner (Arpaia et
al., 2013; Furusawa et al., 2013; Smith et al., 2013) (Figure 4). Treg cells are critical to
maintaining commensal tolerance by the immune system through suppression of aberrant T cell
responses. Unlike other activated T helper subsets, Treg cells have been described to primarily
rely on OXPHOS driven by FAO (Newton et al., 2016). However, signals downstream of TLR
ligation can augment glycolysis and proliferation of Treg cells and reduce their ability to
suppress T cell responses (Gerriets et al., 2016). Retroviral enforced expression of Foxp3
promotes OXPHOS and dampens glucose uptake and glycolysis, whereas Treg cells transduced
with Glut1 decreased Foxp3 expression after adoptive transfer in vivo and fail to suppress T cellmediated colitis in a model of inflammatory bowel disease. These findings suggest that during
inflammation and microbial infection, Treg cells may temporarily lose their regulatory function
to give way to robust T cell responses and participate as more conventional effector helper T
cells. Increases in NaCl either from supplementation in vitro or diet in vivo inhibit the
suppressive function of human Treg cells via serum/glucocorticoid-regulated kinase 1 (SGK1),
which integrates signals from PI3K and mTORC2 to regulate sodium controlled signal
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transduction (Hernandez et al., 2015). However, a study of human Treg cells found that the
glycolytic enzyme enolase-1 was required for their suppressive activity through its control of
Foxp3-E2 splice variants (De Rosa et al., 2015). Depending on environmental cues and
metabolites, it appears that Treg cell metabolism can be modulated, affecting their function.

As discussed, increases in SCFAs either from diet, infection, or exogenous treatment impinge on
metabolic process including HDAC activation (Rooks and Garrett, 2016). A recent study
suggests that activation of the HDAC sirtuin 1 (SIRT1) negatively impacts Th9 cell
differentiation (Wang et al., 2016). The exposure of CD4 T cells to distinct cytokine cocktails
differentiates them into separate helper lineages. However, perturbing metabolism also
modulates CD4 T cell fate. A yin and yang relationship between Th17 and Treg cell
differentiation has been established. Th17 cells are particularly glycolytic and depend on
engagement of this pathway downstream of mTOR and HIF-1α activation. Dampening
glycolysis through deletion of HIF-1α or with the inhibitor 2-DG in T cells impairs Th17
development and instead promotes Treg cells, even under Th17-inducing culture conditions
(Dang et al., 2011; Shi et al., 2011). Suppression of mTOR with rapamycin or genetic ablation
also augments production of Treg cells (Delgoffe et al., 2009; Kopf et al., 2007), and
pharmacological inhibition of de novo fatty acid synthesis prevents Th17 differentiation and
instead enforces a Treg cell phenotype (Berod et al., 2014).

Although the metabolic characteristics of other CD4 T cell subsets have been compared
(Michalek et al., 2011), little was known about Th9 cell metabolism. Th9 cells are characterized
by their ability to produce IL-9 and can be generated from naïve cells in culture using the
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cytokines TGF-β and IL-4. They have implicated roles in autoimmunity, melanoma, and worm
infections (Kaplan et al., 2015). Wang and colleagues found that Th9 cells are highly glycolytic,
in part from their active suppression of SIRT1 expression via the kinase TAK1 (Wang et al.,
2016). SIRT1 was previously shown to negatively control HIF-1α as well as mTOR (Lim et al.,
2010; Liu et al., 2013). In line with this, Th9 cell development was augmented in SIRT1deficient T cells whereas retroviral enforced expression of SIRT1 or dampening of aerobic
glycolysis by chemical or genetic means impaired Th9 cell differentiation (Wang et al., 2016).
Th9, Th17, and Treg cells all share the cytokine TGF-β for their development, but then depend
on additional cytokine signals for their eventual fates. Given their divergent metabolic
phenotypes, as well as HDAC requirements, it would be interesting to explore further whether
variances in intracellular levels of SCFA metabolites for example, might couple with
environment signals to influence their eventual metabolic and development pathway.

Apart from its affect on CD4 T cells, the SCFA acetate also has been shown to affect secondary
recall responses from CD8 memory T cells (Balmer et al., 2016). Germ-free mice reconstituted
with commensal microbes, or oral or systemic infection with bacterial species, elevated serum
acetate concentrations. Memory T cells generated in vitro or in vivo cultured with acetate levels
observed during these infections secreted more IFN-γ and augmented glycolysis after
restimulation. Acetate can be quickly converted into acetyl-CoA, which can condense with
oxaloacetate into citrate in the mitochondria to fuel the TCA cycle and OXPHOS, be used as a
substrate for FAS, or participate in post translational modification (PTM) of proteins including
histones (Pearce et al., 2013). Balmer and colleagues mechanistically tied their results to lysine
acetylation of the glycolytic enzyme GAPDH. GAPDH activity has been shown to regulate T
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cell production of IFN-γ (Chang et al., 2013; Gubser et al., 2013). Although the study
demonstrated that the enzymatic activity of GAPDH was altered by acetylation of K217, whether
this PTM was critical to acetate-dependent increases in IFN-γ protein was not explored. In a
separate report, CD4 T cells deficient in LDHA expression had defects in IFN-γ production,
which stemmed from widespread lack of acetylation of the Ifng locus (Peng et al., 2016). LDHA
is the critical enzyme that defines aerobic glycolysis, converting pyruvate to lactate. Culturing
cells in galactose impairs aerobic glycolysis, as galactose enters glycolysis through the Leloir
pathway at a significantly lower rate than glucose (Bustamante and Pedersen, 1977), a result
confirmed by tracing galactose metabolism in T cells (Chang et al., 2013). Reducing GADPH
engagement from glycolysis in this fashion permits moonlighting function by this abundantly
expressed protein. It was shown that GAPDH binds to the 3’UTR of AU-rich containing
cytokine mRNAs, preventing their efficient translation (Chang et al., 2013). Peng and colleagues
argue against GAPDH posttranscriptional control of T cell function during aerobic glycolysis
deficiency because modification of the 3’UTR of Ifng did not rescue defects in cytokine
production in their system. However as the authors demonstrated, LDHA-deficient cells have
defects in Ifng mRNA production, whereas cells forced to respire in galactose remain as
transcriptionally competent for Ifng as those cultured in glucose. Supplementation with the
SCFA acetate rescued their epigenetic defect and cytokine production. These studies show that
aerobic glycolysis regulates both transcriptional and translational functions in T cells.

While products generated from the microbiome can modulate the metabolism of immune cells
and shift the balance between tolerance and inflammation, there are hints that immune driven
signals central to gut homeostasis may also mediate their effects through metabolic modulation.
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One such example is the pleotropic anti-inflammatory cytokine IL-10. Most hematopoietic cells
produce and sense IL-10 and its importance for maintaining tolerance with the intestinal
microbiota is clearly evident from observations that IL-10 or IL-10R deficient mice develop
spontaneous colitis (Kuhn et al., 1993; Spencer et al., 1998). IL-10R deficiency in macrophages
is also sufficient to recapitulate onset of severe colitis in mice (Shouval et al., 2014; Zigmond et
al., 2014). Further, mice with a myeloid cell-specific deficiency in STAT3, which is activated
downstream of the IL-10R by JAK1, develop chronic enterocolitis as they age (Takeda et al.,
1999). In experiments that shed light on the importance of aerobic glycolysis engagement in DC
activation, it was found that treatment of DCs with recombinant IL-10 blocked increases in their
glycolytic rate after LPS stimulation (Krawczyk et al., 2010). Cells subjected to IL-10R blockade
further upregulated glycolysis after activation compared to controls. It is tempting to speculate
that one of the ways IL-10 might be anti-inflammatory is through inhibition of metabolic
reprogramming to aerobic glycolysis during innate immune cell activation (Figure 4).
Coincidentally, STAT3 was found to localize to mitochondria and interact with ETC complexes,
which helped maintain efficient OXPHOS in the heart (Wegrzyn et al., 2009). Whether
traditional cell surface cytokine-receptor signaling could modulate levels of mitochondrial
STAT3 was not explored. Of interest, CD8 T cells with a conditional deletion of the IL-10R fail
to form memory T cells (Laidlaw et al., 2015), which depend on FAO driven OXPHOS for their
generation after infection (Cui et al., 2015; Pearce et al., 2009; van der Windt et al., 2012).

The gut is one example of a tissue that presents distinct metabolic challenges for immune cells,
which affect their steady state and protective versus inflammatory responses. Other examples,
such as skin, provide the potential for commensal organisms to metabolically affect immune cell
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function, a topic reviewed elsewhere (Hand et al., 2016). The intestinal tract is constantly
subject to fluctuations in diet and sometimes the intake of invasive pathogens can also deprive
metabolic substrates from immune cells. The bacterium Salmonella typhimurium produces a
putative type II asparaginase that depletes available asparagine needed for metabolic
reprogramming of activated T cells via c-Myc and mTOR (Torres et al., 2016). The use of
asparaginase for acute lymphoblastic leukemia treatment highlights the potential for the
depletion of extracellular arginine to significantly affect cellular function (DeBerardinis and
Chandel, 2016). Lack of dietary vitamin B1 decreases the number of naïve B cells in Peyer’s
patches due to their dependence on this TCA cycle cofactor, while leaving IgA+ plasma cells
intact in the lamina propria (Kunisawa et al., 2015). Although ILC metabolism has only recently
been explored (Monticelli et al., 2016; Wilhelm et al., 2016), it was found that in settings of
vitamin A deficiency, type 2 ILCs sustain their function via increased acquisition and utilization
of fatty acids for FAO (Wilhelm et al., 2016) (Figure 4). The internal balance between
polyunsaturated fats and saturated fatty acids can also determine the pathogenicity of Th17 cells;
cells that help maintain mucosal barrier immunity and contribute to pathogen clearance (Wang et
al., 2015a). Long chain fatty acids (LCFA) promote Th1 and Th17 cell polarization and mice fed
with LCFA have exacerbated T cell-mediated autoimmune responses, whereas mice fed with
SCFA are protected (Haghikia et al., 2015). If the internal lipidome of Th17 cells can alter their
function from protective to inflammatory as well as their access to LCFA versus SCFA in the
small intestine, it begs the question of how other tissue systems with a rich diversity of fat
deposits and cells, such as the adipose tissue, modulate the metabolism and function of resident
immune cells.
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Figure 4. Models of metabolic relationships in the gastrointestinal tract
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The gut serves as a direct interface with the outside world and the foods we consume. A single
epithelial cell layer separates the contents of the intestinal lumen from the lamina propria where
DCs, macrophages, ILCs, and T cells reside. Peyer’s patches are interspersed along the
epithelium, which in addition to supporting sampling of luminal antigens by DCs and M cells,
house germinal centers that maturate IgA-secreting B cells with Tfh cell help. B cells augment
glycolysis upon activation and depend on pyruvate import via Mpc2 for longevity as long-lived
plasma cells (LLPCs). Plasma cell hunger for glucose may restrict this nutrient from Tfh cells,
however Tfh cells downregulate glycolysis in response to expression of their lineage defining
transcription factor. In addition, GCs contain areas of hypoxia that impinge on B cell function
like class switch recombination (CSR). Commensal bacteria produce metabolites such as short
chain fatty acids (SCFAs) from the fermentation of dietary fiber, which influence B cell
metabolism and promote IgA secretion. The presence of SCFAs and vitamins support
maintenance of barrier function by promoting the development and survival of Tregs and ILCs,
respectively. Homeostatic signals secreted by gut resident immune cells (e.g. IL-10) may also
modulate metabolism and therefore control their activation state.
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Restructuring of intracellular metabolism

Thus far, we have scrutinized some of the extracellular environmental factors, such as substrate
availability, that influence immune cell metabolism and function. However, other more cellintrinsic processes determine the balance in metabolic pathway usage and subsequent immune
response. Termed “restructuring of intracellular metabolism” here, these internal influences
range from cytoskeletal and organelle structural remodeling to metabolite and redox balance
(Figure 5).

Cytoskeleton and asymmetric cell division
Perhaps one of the most fundamental ways that cellular metabolism is altered in response to
external stimuli is through gross structural changes in intracellular architecture. In an elegant
dissection of PI3K signaling in epithelial cells, Hu and colleagues found cytoskeletal dynamics
and glycolysis to be uniquely intertwined (Hu et al., 2016). The authors showed that addition of
growth factors or insulin activated Rac downstream of PI3K, causing a disruption of the actin
cytoskeleton. Loss of this structural integrity released bound aldolase from filamentous F-actin,
increasing its catalytic activity. Chemical and genetic inhibition of PI3K, Rac, or actin dynamics
modulated glycolysis via mobilization of aldolase (Figure 5). It will be interesting in future
studies to explore how other glycolytic enzymes or even the mitochondria in immune cells
restructure their metabolic activity through changes in cytoskeletal morphology in response to
growth factor or pathogen-derived signals, especially since directed cellular migration is such an
integral feature of how the disseminated immune system can focus its attention on points of
infection or damage. On a related note, two complementary studies have found that in response
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to activation by DCs, lymphocytes asymmetrically partition the metabolic regulators c-Myc and
mTORC1 during the first cell division (Pollizzi et al., 2016; Verbist et al., 2016). This
distribution event determines their eventual destiny wherein the daughter cell that inherits high cMyc expression and mTORC1 activity greatly augments glycolysis and undergoes higher rates of
proliferation during a primary immune response and the other daughter cell maintains the
metabolic profile of a memory T cell with increased persistence and secondary response
capability. The patterning of Myc expression at the inception of the proliferative burst following
activation also regulates a T cell’s capacity to sustain cellular division (Heinzel et al., 2016).

Redox balance and mitochondrial dynamics
The ability to maintain internal metabolite balance is also crucial for supporting the equilibrium
of reductive and oxidizing equivalents such as NAD+/NADH and FAD/FADH2, which
participate in redox reactions that release energy from the oxidation of substrates. Two recent
back-to-back studies demonstrate a requirement for the synthesis of aspartate to balance redox
that may have implications for highly proliferative lymphocytes, such as B and T cells (Birsoy et
al., 2015; Sullivan et al., 2015). For about 20 years, it has been known that cells lacking a
functional ETC possess a defect in proliferation that can be rescued by exogenous pyruvate
(King and Attardi, 1989). However, how pyruvate accomplishes this feat remained untested. In
the absence of a functional ETC, presumably NADH produced from cellular metabolism cannot
be adequately oxidized. Sullivan and colleagues hypothesized that pyruvate may act as a
surrogate electron acceptor to restore redox balance by generating NAD+ during its conversion to
lactate. Indeed, when they added alternative substrates that also result in the oxidation of NADH,
such as α-ketobutyrate, proliferation of cells with impaired ETC function was restored. Birsoy
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and colleagues identified GOT1 through a CRISPR-Cas9 genetic screen as a critical factor for
Jurkat leukemic T cell viability during ETC inhibition (Birsoy et al., 2015). Ultimately both
studies recognized that aspartate, produced via GOT1, to be a critical metabolite for cells to
expand and grow. When the ETC is dysfunctional, electron acceptors become limiting and
aspartate synthesis is impaired that results in a block in cellular proliferation.

As seen above, genetic selection or chemical impairment of the ETC perturbs redox balance, but
a closer examination of mitochondrial dynamics in T cells suggests that physiologic restructuring
of the mitochondria during an immune response also generates changes in redox flow that
mediate metabolic pathway choice during activation and quiescence. Activation initiated by TCR
ligation and binding with costimulatory molecules metabolically reprograms T cells for rapid
anabolic growth and biomass accumulation. Concomitantly, mitochondria undergo biogenesis
and take on a grossly punctate and dispersed morphology with expanded cristae junctions and
augment aerobic glycolysis and OXPHOS (Buck et al., 2016; Ron-Harel et al., 2016). During
this process, the mitochondrial proteome remodels itself to increase mitochondrial one-carbon
metabolism. Knockdown of SHMT2, the first enzyme in this pathway, impairs CD4 T cell
survival and proliferation in vivo (Ron-Harel et al., 2016). It has also been observed that effector
and memory T cells have morphologically distinct mitochondria. Effector T cells have more
“fissed” mitochondria whereas memory T cells have more “fused” mitochondrial networks with
tight cristae suggesting a requirement for mitochondrial fusion in memory T cell metabolism and
homeostasis. Consistent with this observation, antigen-specific T cells lacking the inner
mitochondrial membrane fusion protein Opa1 fail to generate memory T cells after bacterial
infection and have impaired survival in vitro (Buck et al., 2016). The activation, proliferation,
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and function of Opa1 deficient effector T cells however, remain intact. Opa1 KO T cells have
augmented rates of glycolysis and possess mitochondria with diminished OXPHOS efficiency
and malformed cristae compared to controls. We found that in quiescent T cells, such as naïve
and memory T cells, mitochondrial fusion ensured tight cristae associations that allowed for the
ETC to function efficiently. On the other hand, mitochondrial fission directed cristae expansion
during immune cell activation physically separated ETC complexes and decreased ETC
efficiency, thereby disrupting cellular redox balance. In order to correct this redox imbalance,
cells exported lactate from pyruvate conversion and in doing so, supported their commitment to
aerobic glycolysis. These data suggest a model whereby the structural remodeling of
mitochondria can signal the engagement of a particular metabolic pathway (Figure 5).

Tight associations of mitochondrial cristae result in dense packing of ETC complexes, which
have been found to associate in specialized configurations termed respiratory supercomplexes or
respirasomes. Supercomplexes facilitate efficient transfer of electrons and minimize proton leak
during ATP production (Cogliati et al., 2013). Research into this area is still growing, but a
couple of studies have highlighted their contributions to immune responses. CD8 T cells express
high levels of methylation-controlled J protein (MCJ), a member of the DnaJ family of
chaperones (Champagne et al., 2016). MCJ localizes to the inner membrane of mitochondria and
associates with complex I of the ETC. By doing so, it negatively regulates the assembly of
complex I into supercomplexes. MCJ deficiency was found to enhance naïve and activated CD8
T cell OXPHOS and a unique attribute was its role in the secretion, but not the translation, of
effector cytokines (Champagne et al., 2016). Increased respiration efficiency improved the
survival of the MCJ KO effector T cells, which also induced superior protective immunity
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against viral challenge. Boosting oxidative capacity through enforcement of mitochondrial fusion
also extends the survival and function of CD8 T cells in vivo (Buck et al., 2016). A separate
study in myeloid cells found that TLR and inflammasome dependent bacterial recognition by
macrophages induces a transient decrease of complex I respirasome assembly while enhancing
complex II activity (Garaude et al., 2016). Inhibition of complex II (a.k.a. SDH – succinate
dehydrogenase) in vivo disrupted production of IL-1β after infectious challenge while enhancing
levels of the anti-inflammatory cytokine IL-10.

Itaconate and ROS
In relation to the role of SDH in macrophage cytokine production, a key example of an
intracellular metabolite impinging on immune cell metabolism and response outcome is provided
by itaconate. A comprehensive description of its discovery as an antimicrobial metabolite and
modulator of immune cell bioenergetics has been reviewed recently (Luan and Medzhitov,
2016). Upon activation, downstream of inflammatory stimuli such as TLR signaling,
macrophages increase their internal concentrations of the metabolite itaconate by conversion of
TCA cycle derived aconitate via the mitochondria-associated enzyme immunoresponsive gene 1
(Irg1). Itaconate in turn competitively inhibits SDH function, resulting in succinate accumulation
(Lampropoulou et al., 2016). Itaconate can also impair OXPHOS in a dose dependent manner
(Cordes et al., 2016). Therefore, production of itaconate may necessitate the switch to aerobic
glycolysis that occurs in myeloid cells after LPS stimulation by introducing a brake in the TCA
cycle and ETC through SDH inhibition. However the situation is a bit more complicated (Figure
5). Inflammatory cytokine production from activated myeloid cells is also coupled to
commitment to ATP generation via aerobic glycolysis (O'Neill and Pearce, 2016). Exogenous
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treatment with itaconate inhibits production of IL-1β, IL-6, IL-12, and ROS in response to
inflammatory signals, while Irg1 deficient macrophages have increased inflammatory cytokine
output (Lampropoulou et al., 2016). Irg1 KO cells have intact SDH activity and their hyper
inflammatory phenotype agrees with a recent study demonstrating a requirement for SDH
dependent IL-1β generation in LPS activated macrophages (Mills et al., 2016). Mills, Kelly and
colleagues propose a model whereby IL-1β production is dependent on ROS generated from the
oxidation of accumulated succinate that is driven by reverse electron transport (RET) from intact
SDH. This builds from a previous report demonstrating that glutamine dependent succinate
accumulation after LPS stimulation via glutamine-dependent anarplerosis and the γ-aminobutyric
acid shunt pathway is important for augmenting glycolysis through HIF-1α stabilization and IL1β production from macrophages (Tannahill et al., 2013). However, Lampropoulou and
colleagues describe succinate accumulation driven by itaconate inhibition of SDH. One possible
explanation that unifies these observations is that initial signals downstream of TLR activation
drive succinate production from glutamine to initiate ROS and generate IL-1β. Itaconate, later
accumulates as Irg1 levels increase and feeds back on SDH to inhibit its activity and sets a
threshold for inflammatory cytokine production (Luan and Medzhitov, 2016). In doing so, both
processes may also initiate and sustain myeloid cell commitment to aerobic glycolysis.

The generation of mitochondrial-derived ROS has been shown to be important for macrophage
activation and inflammatory cytokine production and also critical for the activation and
expansion of antigen-specific T cells (Mills et al., 2016; Sena et al., 2013; Tannahill et al., 2013).
However, immune cells can generate ROS from other intracellular compartments apart from the
mitochondrial ETC. Cellular superoxide anions can be released from the NADPH oxidase
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(NOX), which assembles on the phagolysosome to aid in the destruction of ingested
microorganisms. ROS derived from NOX has been previously shown to be critical for the
activation of the NLRP3 inflammasome (Abais et al., 2015). However, a study from Moon and
colleagues extends a role for NOX4 in the activation of the NLRP3 inflammasome through its
modulation of FAO (Moon et al., 2016). NOX4 deficient mouse and human macrophages
stimulated in vitro with ATP, nigericin, or silica had impaired caspase-1 activation and
subsequent IL-1β and IL-18 maturation, although TNF-α production remained intact.
Inflammasome activation was also diminished in NOX4 KO mice after S. pneumoniae challenge.
This defect was identified as an inability of NOX4 deficient cells to augment Cpt1a dependent
FAO during inflammasome activation.

Consistent with this observation, Cpt1a deficient

macrophages were unable to activate the NLPR3 inflammasome, but enforced expression of
Cpt1a in NOX4 KO macrophages rescued inflammasome activation and cytokine release
(Figure 5). However, exactly how NOX4 regulates Cpt1a protein levels and FAO is unresolved.
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Figure 5. Restructuring of intracellular architecture and metabolism.
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Immune cell function is a product of their metabolic state. Growth factor signaling, actin
rearrangement, and glucose metabolism are closely intertwined. Actin-bound aldolase can be
freed from the cytoskeleton downstream of growth factor signaling to mediate glycolysis.
Engagement of this pathway is central to the activation and downstream effector functions of
DCs, M1 macrophages, and T cells. T cells can dynamically restructure their mitochondria
through processes like mitochondrial fission and fusion to signal changes in metabolism and to
promote long-term survival as they transition to memory cells. Inflammatory signals repurpose
TCA cycle enzymes and metabolic intermediates such as itaconate, succinate, and processes like
FAO to serve as internal signals that modulate ROS production, inflammasome activation, and
cytokine production.
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Outlook

Immunology for some time became a field that sought reductionist approaches to simplify a
complex network of cells. Out of necessity, immunologists had to speak a common language or
jargon that often excluded scientists in other disciplines. After many decades of hard work, great
strides have been made in our understanding of the immune system and now immunologists are
better equipped to cross over into other disciplines. It is this ‘take a step back and look’ approach
that has led a number of laboratories to focus on metabolism and how this affects the immune
system as well as its greater impact in tissue physiology.

It is obvious to most biologists that metabolism is integrated into every cellular process and fate
decision. After all, everything must eat to survive. However, what is perhaps less appreciated is
that the immune system is like a liquid organ unto itself. At their inception, immune cells are
poised to respond to unknown stimuli, nutrients, pathogens and are akin to special agents with
contingency plans, ready to respond to one disaster scenario after another, or may be relegated to
pushing paperwork at the office maintaining the status quo. We have only highlighted some
examples of the complexity of the situations and environments that immune cells face that
provide various metabolic instructional cues throughout this review. This ability to rapidly
change and adapt at any given second means that immune cells must intimately integrate their
cellular metabolism in a way that most other organ and cell systems in the body do not have to,
which we hope this review has shown and inspires research into many questions that remain to
be explored. Coupling the unique benefits of studying immunometabolism is the added bonus of
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the enormous clinical relevance of these cells in human health and disease. First defining and
then exploiting their unique metabolism may continue to yield new targets for therapy.
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Chapter 3: Materials and Methods
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Mice and immunizations
C57BL/6, C57BL/6 CD45.1, C57BL/6 CD90.1, photo-activatable mitochondria (PhAM), and
major histocompatibility complex (MHC) class I-restricted OVA specific TCR OT-I transgenic
mice were purchased from The Jackson Laboratory. Mfn1 and Mfn2 conditional floxed mice
were obtained from Dr. David C. Chan (California Institute of Technology, Pasadena, CA).
Opa1 conditional floxed mice were obtained from Dr. Hiromi Sesaki (Johns Hopkins University
School of Medicine, Baltimore, MD). All conditional floxed mice were crossed to OT-I CD4 Cre
transgenic mice to generate OT-I Mfn1F/F CD4 Cre, OT-I Mfn2F/F CD4 Cre, and OT-I Opa1F/F
CD4 Cre mice. All mice were bred and maintained under specific pathogen free conditions under
protocols approved by the AAALAC accredited Animal Studies Committee of Washington
University School of Medicine, St. Louis, MO USA and the Animal Welfare Committee of the
Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany. Age matched mice
were injected intraperitoneally (i.p.) or intravenously (i.v.) as indicated with a sublethal dose of
1x106 colony forming units (CFU) of recombinant Listeria monocytogenes expressing OVA
deleted for actA (LmOVA) for primary immunizations and challenged with 5x107 CFU for
secondary immunizations. For tumor experiments, 1x106 EL4 lymphoma cells expressing OVA
(EL4-OVA) were injected subcutaneously (s.c.) into the right flank of mice.

Cell culture and drug treatments
OT-I splenocytes were activated with OVA-peptide (SIINFEKL, New England Peptide) and IL-2
(100 U/mL) for 3 days and subsequently cultured in the presence of either IL-2 or IL-15 (10
ng/mL) for an additional 3 days in TCM (RPMI 1640 media supplemented with 10% FCS, 2 mM
L-glutamine, 100 U/mL penicillin/streptomycin, and 55 µM β-mercaptoethanol). For drug

74

treatment experiments, vehicle control (DMSO) or 10 µM Mdivi-1 + 20 µM M1 (Sigma) were
added to cultures daily starting on day 3. For in vitro survival assays, cells were activated for 3
days as described, then cultured in either IL-2 at 5x104 cells/mL or IL-15 at 1x105 cells/mL in 96
well round bottom plates. Survival was analyzed by 7AAD exclusion using flow cytometry.
Bone marrow cells were differentiated for 7 days into BM-Macs by culturing in complete
medium (RPMI 1640 supplemented with 10% FBS, 100 U/mL penicillin/streptomycin, 2 mM Lglutamine) with 20 ng/mL mouse macrophage colony-stimulating factor (M-CSF; PeproTech) or
into BM-DCs using 20 ng/mL granulocyte-macrophage colony-stimulating factor (GM-CSF;
PeproTech). BM-Macs and BM-DCs were stimulated using 20 ng/mL LPS (Sigma), 50 ng/mL
IFN-γ (R&D Systems), or 20 ng/mL IL-4 (PeproTech). BM-DCs were cultured in 5 ng/mL GMCSF during stimulation experiments.

Flow cytometry and spinning disk confocal microscopy
Fluorochrome-conjugated monoclonal antibodies were purchased from eBioscience, BD
Pharmingen, or Biolegend and staining performed as previously described (Chang et al., 2015).
OVA-specific CD8+ T cells from spleen, lymph node, or blood were quantified by direct staining
with H2-KbOVA257-264 (KbOVA) MHC-peptide tetramers. MitoTracker, TMRM, CMxROS,
MitoSOX, and Hoechst staining was performed according to the manufacturer’s instructions
(Life Technologies). Nos2 protein levels in BM-Macs were quantified after fixation and
permeabilization using the transcription factor staining buffer set (eBioscience) and a directly
conjugated antibody against Nos2 (clone CXNFT, eBioscience). Cells were collected on FACS
Calibur, Canto II, LSR II, and Fortressa flow cytometers (BD Biosciences) and analyzed using
FlowJo (TreeStar) software. Cells were sorted using a FACS Aria II. Cells were imaged live on
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glass bottom dishes coated with fibronectin or poly-D-lysine (Sigma) in TCM containing IL-2 or
IL-15 (MatTek) using a LSM 510 META confocal scanning microscope (Zeiss), an Olympus
Confocal Microscope FV1000, or a Zeiss spinning disk confocal with an Evolve (EMCCD)
camera. Cells were kept in a humidified incubation chamber at 37°C with 5% CO2 during image
collection. Images were deconvolved and analyzed using ImageJ (NIH). Brightness and contrast
were adjusted in Adobe Photoshop CS.

Transmission electron microscopy
Cells were fixed in 2% paraformaldehyde, 2.5% glutaraldehyde in 100 mM sodium cocodylate
containing 0.05% malachite green. Following fixation, samples were washed in cocodylate
buffer and post fixed in 1% osmium tetroxide. After extensive washing in H2O, samples were
stained with 1% aqueous uranyl acetate for 1 hour and washed again. Samples were dehydrated
in ethanol and embedded in Eponate 12 resin (Ted Pella). Cut sections were stained with uranyl
acetate and lead citrate and then imaged using a JOEL 1200 EX transmission electron
microscope equipped with an 8 MP ATMP digital camera (Advanced Microscopy Techniques).

Metabolism assays
Oxygen consumption rates (OCR) and extracellular acidification rates (ECAR) were measured in
XF media (non-buffered RPMI 1640 containing 25 mM glucose, 2mM L-glutamine, and 1 mM
sodium pyruvate) under basal conditions and in response to 200 µM etomoxir (Tocris), 1 µM
oligomycin, 1.5 µM fluoro-carbonyl cyanide phenylhydrazone (FCCP) and 100 nM rotenone + 1
µM antimycin A, or 50 ng/mL phorbol 12-myristate 13-acetate (PMA) + 500 ng/mL ionomycin
(all Sigma) using a 96 well XF or XFe Extracellular Flux Analyzer (EFA) (Seahorse Bioscience)
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(van der Windt et al., 2016). For mitochondrial fission inhibition experiments, cells were plated
in XF media containing 10 µM Mdivi-1 or vehicle control (DMSO), followed by injection into
port A with XF media, αCD3/CD28- conjugated beads (1 bead/cell; Dynabeads), or 20 ng/mL
LPS ± 50 ng/mL IFN-γ.

Glucose tracing
Cells were activated with OVA peptide and cultured in glucose free TCM (prepared with
dialyzed FBS) supplemented with 11 mM glucose. On day 3 of culture, cells were washed and
cultured overnight in TCM replaced with 11 mM D-[1,213C] labeled glucose. For harvest, cells
were rinsed with cold 150    mM ammonium acetate (NH4AcO), and metabolites extracted using
1.2 mL of 80% MeOH kept on dry ice. 10 nM norvaline (internal standard) was added.
Following mixing and centrifugation, the supernatant was collected, transferred into glass vials
and dried via centrifugal evaporation. Metabolites were resuspended in 50    µL 70% ACN and
5    µL of this solution used for mass spectrometer-based analysis performed on a Q Exactive
(Thermo Scientific) coupled to an UltiMate 3000RSLC (Thermo Scientific) UHPLC system.
Mobile phase A was 5    mM NH4AcO, pH 9.9, B was ACN, and the separation achieved on a
Luna 3u NH2 100A (150 × 2.0    mm) (Phenomenex) column. The flow was kept at 200    µL/min,
and the gradient was from 15% A to 95% A in 18    min, followed by an isocratic step for 9    min
and re-equilibration for 7    min. Metabolites we detected and quantified as area under the curve
(AUC) based on retention time and accurate mass (≤ 3    p.p.m.) using TraceFinder 3.3 (Thermo
Scientific) software.
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Adoptive transfers
For in vivo memory T cell experiments, ≤1x104 OT-I+ CD8+ cells/mouse from donor splenocytes
were transferred intravenously (i.v.) into congenic recipient mice. Blood samples or spleens were
collected at indicated time points and analyzed by flow cytometry. For in vivo survival
experiments, 1-2x106 day 6 IL-2 TE treated cells/mouse were injected i.v. into naïve C57BL/6
mice. Cells were recovered two days later from the spleen or lymph nodes and analyzed by flow
cytometry or isolated from spleens >3 weeks 6 days after LmOVA infection. For adoptive
cellular immunotherapy experiments, 1-5x106 day 6 IL-2 TE treated cells/mouse were injected
i.v. into previously EL4-OVA tumor inoculated mice and measured for tumor volume growth.

RT-PCR and western blotting
RNA isolations were done by using the RNeasy kit (Qiagen) and single-strand cDNA was
synthesized using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems).
Genomic DNA was extracted using the QIAamp DNA micro kit (Qiagen) to determine
mtDNA/nDNA ratios. All RT-PCR was performed with Taqman primers using an Applied
Biosystems 7000 sequence detection system. The expression levels of mRNA were normalized
to the expression of a housekeeping gene (β-actin). For western blot analyses, cells were washed
with ice cold PBS and lysed in 1x lysis buffer (Cell Signaling Technologies) supplemented with
1 mM PMSF. Samples were freeze-thawed 3 times and centrifuged at 20,000xg for 10 min at
4°C. Cleared protein lysate was denatured with LDS loading buffer for 10 min at 70°C. For
native lysis, cells were resuspended in native lysis buffer (Life Technologies), supplemented
with increasing percentages of digitonin, MgCl, and micrococcal nuclease. After nuclease
incubation at RT for 1h, lysates were cleared by centrifugation at 20,000xg for 30 min at 4°C.
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For mitochondrial membrane solubilization analyses, both the cleared supernatant and pellet
were denatured with LDS loading buffer for 10 min at 70°C. Samples were run on precast 4-12%
bis-tris protein gels (Life Technologies). Proteins were transferred onto nitrocellulose
membranes using the iBLOT 2 system (Life Technologies). Membranes were blocked with 5%
w/v milk and 0.1% Tween-20 in TBS and incubated with the appropriate antibodies in 5% w/v
BSA in TBS with 0.1% Tween-20 overnight at 4°C. The following antibodies were used: Opa1
(BD), rodent OXPHOS complex proteins cocktail (Abcam), Calnexin (Santa Cruz), and β-Actin,
Mfn2, Drp1, Drp1pS616 (Cell Signaling Technologies). All primary antibody incubations were
followed by incubation with secondary HRP-conjugated antibody (Pierce) in 5% milk and 0.1%
Tween-20 in TBS and visualized using SuperSignal West Pico or femto Chemiluminescent
Substrate (Pierce) on Biomax MR film (Kodak).

Retroviral transduction
Activated OT-I splenocytes were transduced with control (empty vector) or Mfn1, Mfn2, Opa1
expressing retrovirus by centrifugation for 90 minutes in media containing hexadimethrine
bromide (8 µg/mL; Sigma) and IL-2 (100 U/mL). GFP or human CD8 were markers for
retroviral expression.

Cytotoxicity assay
EL4-OVA tumor cells were pre-treated with 100 U/mL murine IFN-γ for 24 hours before use. To
generate target cells, 1x106 tumor cells were labeled with 0.5 µM Cell Proliferation Dye e670
(eBioscience) in PBS for 8 minutes at room temperature, washed twice with PBS and 10,000
cells were seeded per well in 96-well round bottom plates. IL-2 TE cells treated with DMSO or
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M1+Mdivi-1 were co-cultured with target cells at the indicated effector/target cell ratios and
incubated for 12 hours at 37°C in 5% CO2. To generate reference cells, 1x106 tumor cells were
labeled with 5 µM Cell Proliferation Dye e670 in PBS and incubated on ice. 10,000 reference
cells were added before cells were stained with Po-ProTM-1 dead cell staining dye (Life
Technologies). IL-2 TE cell killing efficiency was analyzed by flow cytometry and data defined
as percentage of live cells normalized to reference cells.

Statistical analysis
Comparisons for two groups were calculated using unpaired two-tailed student’s t-tests,
comparisons for more than two groups were calculated using one-way ANOVA followed by
Bonferroni’s multiple comparison tests. Comparisons over time were calculated using two-way
ANOVA followed by Bonferroni’s multiple comparison tests.
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Introduction

T cells are important mediators of protective immunity against pathogens and cancer and have
several unique properties, not least of which is their ability to proliferate at a rate arguably unlike
any other cell in an adult organism. In this regard, one naïve T cell can clonally expand into
millions of ‘armed’ TE cells in just a few days (Williams and Bevan, 2007). Concomitant with T
cell activation is the engagement of Warburg metabolism, a metabolic phenotype shared by
cancer cells and unicellular organisms (Fox et al., 2005; Vander Heiden et al., 2009). Once the
source of antigen is cleared, most antigen-specific cells die, but a subset of long-lived, resting TM
cells persists (Kaech et al., 2003). TM cells have a unique metabolism that renders them equipped
to rapidly respond should infection or tumor growth recur (Pearce et al., 2013). These extensive
changes in phenotype and function of T cells go hand in hand with a highly dynamic metabolic
range (Buck et al., 2015; MacIver et al., 2013). As such, these cells represent a distinctive and
amenable system in which we can study marked changes in cellular metabolism that occur as
part of normal cellular development, and not as a result of transformation.

Both OXPHOS and aerobic glycolysis generate energy in the form of ATP, but importantly, are
also critical for other essential processes such as the building of biosynthetic precursors for
biomass, the production of reactive oxygen species (ROS), and the balance of reducing/oxidizing
equivalents like NADH/NAD+ which take part in redox reactions that release energy from
nutrients. Naïve T (TN) cells use OXPHOS for their metabolic needs, but both OXPHOS and
aerobic glycolysis are augmented upon activation (Chang et al., 2013; Sena et al., 2013). The
latter is characterized by the preferential conversion of pyruvate to lactate in the cytoplasm rather
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than its oxidation in the TCA cycle. TM cells predominantly use OXPHOS like TN cells, but have
enhanced mitochondrial capacity that is marked by their reliance on FAO to fuel OXPHOS (van
der Windt et al., 2012; van der Windt et al., 2013). Failure to engage specific metabolic
programs impairs the function and differentiation of T cells (Pearce and Pearce, 2013).
Establishing the precise reasons why, and how, these and other cells emphasize one particular
metabolic pathway over another remains a challenging prospect.

Mitochondria are essential hubs of metabolic activity, antiviral responses, and cell death
(Nunnari and Suomalainen, 2012). These dynamic organelles constantly remodel their structure
through fission and fusion events mediated by highly conserved nuclear encoded GTPases
(Ishihara et al., 2013; Youle and van der Bliek, 2012). Mitochondrial fission generates smaller,
discrete and fragmented mitochondria that can increase ROS production (Yu et al., 2006),
facilitate mitophagy (Frank et al., 2012), accelerate cell proliferation (Marsboom et al., 2012;
Taguchi et al., 2007), and mediate apoptosis (Youle and Karbowski, 2005). Dynamin-related
protein 1 (Drp1) is a cytosolic protein that translocates to the outer mitochondrial membrane
(OMM) upon phosphorylation to scission mitochondria (Ingerman et al., 2005; Labrousse et al.,
1999; Wakabayashi et al., 2009). Fusion of mitochondria into linear or tubular networks limits
deleterious mutations in mitochondrial DNA (mtDNA) (Santel et al., 2003), induces
supercomplexes of the ETC maximizing OXPHOS activity (Cogliati et al., 2013; Mishra et al.,
2014; Zorzano et al., 2010), and enhances endoplasmic reticulum (ER) interactions important for
calcium flux (de Brito and Scorrano, 2008). In addition, mitochondria elongate as a survival
mechanism in response to nutrient starvation and cell stress, linking fusion to cellular longevity
(Friedman and Nunnari, 2014; Gomes et al., 2011; Rambold et al., 2011a). OMM fusion is
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mediated by mitofusin 1 and 2 (Mfn1, Mfn2) isoforms (Chen et al., 2003), while inner
membrane fusion is controlled by optic atrophy 1 (Opa1) protein (Cipolat et al., 2004). Complete
organismal deficiency in any of these proteins is embryonically lethal and mutations in the genes
that encode them underlie the cause of several human diseases (Archer, 2014; Chan, 2012; Chen
et al., 2007; Zhang et al., 2011).

Mitochondrial membrane remodeling has been largely demonstrated to be acutely responsive to
changes in cellular metabolism (Mishra and Chan, 2016; Wai and Langer, 2016), but whether it
plays a dynamic role in shaping metabolic pathways has been inferred but not extensively
studied. At the cellular level, deletion of any of the fission and fusion machinery perturbs
OXPHOS and glycolytic rates at baseline (Liesa and Shirihai, 2013). Tissue-specific deletion of
Mfn2 in muscles of mice disrupts glucose homeostasis (Sebastian et al., 2012) and Drp1 ablation
in the liver results in reduced adiposity and elevated whole-body energy expenditure, protecting
mice from diet-induced obesity (Wang et al., 2015b). A recent study has also suggested a link
between Drp1 mediated fission and its affect on glycolysis during cell transformation
(Serasinghe et al., 2015). The central question of whether fission/fusion and associated changes
in cristae morphology actively control the adoption of distinct metabolic programs and therefore
regulates T cell responses however, remains unanswered.
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Unlike TE cells, TM cells maintain a fused mitochondrial network

We reported that TM cells have more mitochondrial mass than TE or TN cells and suggested that
mitochondria in these T cell subsets possess distinct morphologies (van der Windt et al., 2012;
van der Windt et al., 2013). These observations prompted us to more closely assess
mitochondrial structure in T cells. We infected mice with Listeria monocytogenes expressing
ovalbumin (OVA) (LmOVA) and isolated TE and TM cells for ultrastructure analysis by electron
microscopy (EM). We found that TE cells had small, distinct mitochondria dispersed in the
cytoplasm, while TM cells had more densely packed, somewhat tubular, mitochondria (Figure
6A). In order to more thoroughly investigate these morphological differences, we differentially
cultured activated OVA-specific T cell receptor (TCR) transgenic OT-I cells in interleukin-2 (IL2) and IL-15 to generate IL-2 TE and IL-15 TM cells (Figure 7) (Carrio et al., 2004). These
culture conditions approximate T cell responses in vivo and allow us to generate large numbers
of cells amenable to further experimentation in vitro (O'Sullivan et al., 2014). We found that IL2 TE and IL-15 TM cells possessed similar mitochondrial ultrastructure as their ex vivo isolated
counterparts (Figure 6B). Next, we acquired live Z-stacked images of these T cells over time by
confocal microscopy and found that while at day 1 after activation the mitochondria appeared
fused, from days 2-6 after activation, IL-2 TE cells exhibited predominantly punctate
mitochondria (Figure 6C). In contrast, once cells were exposed to IL-15, a cytokine that
supports TM cell formation (Schluns et al., 2002), the mitochondria formed elongated tubules
(Figure 6C). Magnified 3D rendered images from these experiments emphasized the marked
differences in mitochondrial morphology between the IL-2 TE and IL-15 TM cells (Figure 6D).
Together these data suggest that the mitochondria in TE cells are actively undergoing fission,
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while in TM cells, these organelles exist in a fused state. To further investigate these changes in
mitochondrial morphology, we assessed the expression of several critical protein regulators of
mitochondrial dynamics. We found that by day 6, fusion mediators Mfn2 and Opa1 were lower
in TE cells compared to TM cells, while fission factor Drp1 was more highly phosphorylated at its
activating site Ser616 in TE cells (Figure 6E) (Marsboom et al., 2012). These data are consistent
with our observations that mitochondria in TM cells appear more fused than those in TE cells.
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Figure 6. Effector and memory T cells possess distinct mitochondrial morphologies.
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(A) C57BL/6 mice were infected i.p. with 1x107 CFU LmOVA. Effector (TE, CD44hi CD62Llo, 7
days post infection) and memory T (TM, CD44hi CD62Lhi, 21 days post infection) cells were
sorted and analyzed by EM as well as (B) IL-2 TE and IL-15 TM cells generated from differential
culture of OT-I cells activated with OVA peptide and IL-2 using IL-2 or IL-15, scale bar = 0.5
µm. (C-D) Mitochondrial morphology was analyzed in live OT-I PhAM cells over time before
and after αCD3/CD28 activation and differential cytokine culture by spinning disk confocal
microscopy. Mitochondria are green (GFP) and nuclei are blue (Hoechst). (C) Scale bar = 5 µm,
(D) Scale bar = 1 µm. (E) Immunoblot analysis of cell protein extracts from (C), probed for
Mfn2, Opa1, Drp1, phosphorylated Drp1 at Ser616 (Drp1pS616), and β-actin. (A-E) Results
representative of 2 experiments.
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Figure 7. In vitro differentiation of IL-2 TE and IL-15 TM cells approximate T cell response
conditions that generate TE and TM cells in vivo.

OT-I cells were activated with IL-2 and either OVA peptide or αCD3/CD28 for 3 days and then
differentially cultured in IL-2 or IL-15 for an additional 3 days to generate IL-2 TE and IL-15 TM
cells, respectively.
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Mitochondrial inner membrane fusion protein Opa1 is necessary for TM cell generation

We questioned next whether mitochondrial fusion was important for TM cell generation and
survival. We crossed Mfn1, Mfn2, and Opa1 floxed mice to OT-I CD4 Cre transgenic mice to
conditionally delete these proteins in T cells. Peripheral T cell frequencies in these mice were
grossly normal (data not shown). We differentially cultured these Mfn1-/-, Mfn2-/-, and Opa1-/OT-I T cells in IL-2 and IL-15 and found that only Opa1-/- T cells displayed a selective defect in
survival when cultured in IL-15 (Figure 8A). Opa1 deficiency did not effect IL-2 TE cell
survival. We measured the efficiency of gene deletion by mRNA and/or protein analyses (Figure
9A-C). While Mfn1 and 2 were efficiently deleted, we found some residual expression of Opa1
particularly in IL-15 TM cells, suggesting that we were selecting for cells that retained expression
of Opa1 in IL-15 culture conditions, albeit at a diminished level as most of these cells die
(Figure 8A). We also assessed mitochondrial ultrastructure and, in agreement with published
results for other cell types (Cogliati et al., 2013; Zhang et al., 2011), mitochondrial cristae were
significantly altered and disorganized in the absence of Opa1 (Figure 8B). Consistent with their
survival defect, Opa1-/- IL-15 TM cells exhibited decreased OXPHOS activity, as measured by O2
consumption rate (OCR, an indicator of OXPHOS) to extracellular acidification rate (ECAR, an
indicator of aerobic glycolysis) ratio, and spare respiratory capacity (SRC), compared to normal
cells (Figure 8C). SRC is the extra mitochondrial capacity available in a cell to produce energy
under conditions of increased work or stress and is thought to be important for long-term cellular
survival and function (measured as OXPHOS activity above basal after uncoupling with FCCP)
(Choi et al., 2009; Ferrick et al., 2008; Nicholls, 2009; Nicholls et al., 2010; van der Windt et al.,
2012; Yadava and Nicholls, 2007). To determine whether Opa1 function is required for TM cell
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development in vivo, we adoptively transferred naïve Opa1-/- OT-I T cells into congenic
recipients, infected these mice with LmOVA, and subsequently assessed TM cell formation in the
weeks after infection. Control and Opa1-/- OT-I T cells mounted normal TE cell responses (day 7)
to infection, while Opa1-/- OT-I TM cell formation (days 14-21) was drastically impaired (Figure
8D). Consistent with diminished TM cell development, a significantly higher proportion of shortlived effector cells to memory precursor effector cells were present within the Opa1-/- OT-I
donor cell population 7 days after infection (Figure 9D) (Kaech et al., 2003). In addition, at day
10 post-infection, a time point at which TE cells contract, while TM cells emerge, Opa1-/- T cells
isolated ex vivo had decreased SRC compared to control cells (Figure 9E), correlating with their
decreased survival. To assess whether Opa1-/- TM cells existed in too low an abundance to be
discerned by flow cytometry, we challenged these mice with a second infection. We observed no
recall response (day 3 and 6 p.c.) from Opa1-/- T cells when assessing frequency (Figure 8E) or
absolute numbers (Figure 8F), while there was considerable expansion of control donor cells.
These data illustrate that Opa1 function is required for TM cell, but not TE cell generation.
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Figure 8. Memory T cell development and survival, unlike effectors, requires
mitochondrial fusion.
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(A) Relative in vitro survival ratios of Mfn1, Mfn2, or Opa1 deficient (CD4 Cre+, -/-) to wildtype control (CD4 Cre-, +/+) OT-I IL-2 TE and IL-15 TM cells (*p=0.0465). Data normalized
from 2-3 independent experiments shown as mean ± SEM. (B) Mitochondrial morphology of
OT-I Opa1 wild-type and Opa1 knockout IL-2 TE and IL-15 TM cells analyzed by EM (scale bar
= 0.5 µm, one experiment represented) and (C) Seahorse EFA. (Left) bar graph represents ratios
of O2 consumption rates (OCR, an indicator of OXPHOS) to extracellular acidification rates
(ECAR, an indicator of aerobic glycolysis) at baseline and (right) spare respiratory capacity
(SRC) (% max OCR after FCCP injection of baseline OCR) of indicated cells (*p<0.03,
**p=0.0079). Data from 3 experiments shown as mean ± SEM. (D-F) 104 OT-I Opa1+/+ or Opa1/-

T cells were transferred i.v. into C57BL/6 CD90.1 mice infected i.v. with 1x107 CFU LmOVA.

Blood was analyzed by flow cytometry at indicated time points post infection. After 21 days,
mice were challenged i.v. with 5x107 CFU LmOVA and blood analyzed post challenge (p.c.).
(D) % Donor Kb/OVA+ and CD90.2+ live cells shown in representative flow plots and (E) line
graph with mean ± SEM. (*p=0.0238, **p<0.005). (F) Number of donor Kb/OVA+ cells isolated
from spleens of infected mice shown as mean ± SEM (*p=0.0126). (D-F) Results representative
of 2 experiments (n=9-11 per group).
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Figure 9. Assessment of genetic deletion of mitochondrial fusion proteins in IL-2 TE and
IL-15 TM cells and of donor TE cells generated from infection.
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(A-C) IL-2 TE and IL-15 TM cells were cultured from (A) OT-I Mfn1 floxed, (B) OT-I Mfn2
floxed, (C) OT-I Opa1 floxed mice crossed to CD4 Cre transgenic mice to generate T cells
conditionally deleted for proteins that mediate mitochondrial fusion (+/+ are CD4 Cre- and -/- are
CD4 Cre+). Efficiency of deletion by cre recombinase analyzed by (A) qPCR and (B-C)
immunoblot. (D) Flow cytometry analysis of short-lived effector cells

(SLEC, KLRG1hi

CD127lo) and memory precursor effector cells (MPEC, KLRG1lo CD127hi) generated at day 7
post infection from OT-I Opa1+/+ and OT-I Opa1-/- cells transferred into congenic recipients
infected with LmOVA. Representative flow dot plots (left) and scatter dot plots (right) with
mean ± SEM bars. Each dot represents individual mice (n=8-9 per genotype), ***p<0.0001. (E)
OCR analysis of day 10 post-infection OT-I Opa1+/+ and Opa1-/- donor cells at baseline and after
oligomycin (Oligo), FCCP, and rotenone plus antimycin A (R+A) injections. Data is
representative of 2 experiments shown as mean ± SEM.
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Mitochondrial fusion imposes a TM cell phenotype, even in the presence of activating
signals
Genetic loss of function of Opa1 revealed that this protein is critical for TM cell formation. Given
the fused phenotype of mitochondria in these cells, we hypothesized that Opa1-mediated
mitochondrial fusion supports the metabolism needed for TM cell development. We used a gain
of function approach to enhance mitochondrial fusion. Culturing T cells with the ‘fusion
promoter’ M1 (Wang et al., 2012), and the ‘fission inhibitor’ Mdivi-1 (Cassidy-Stone et al.,
2008) (Figure 10A), induced mitochondrial fusion in IL-2 TE cells, rendering them
morphologically similar to IL-15 TM cells (Figure 10B). Treatment with these drugs enhanced
other TM cell properties in activated IL-2 TE cells, including increased mitochondrial mass
(Figure 10C), OXPHOS and SRC (Figure 10D), CD62L expression (Figure 10E) and robust
metabolic activity, as indicated by bioenergetic profiling of the cells in response to secondary
stimulation with PMA/ionomycin, followed by addition of oligomycin (ATP synthase inhibitor),
FCCP, and rotenone plus antimycin A (ETC complex I and III inhibitors), all drugs that stress
the mitochondria (Figures 10F and 11A) (Nicholls et al., 2010). However, we did not observe
increased mtDNA in these cells (Figure 11B). We found that ECAR and the OCR/ECAR ratio
increased after drug treatment (Figure 11C), indicating elevated metabolic activity overall, with
a predominant increase in OXPHOS over glycolysis. While we observed these changes in
mitochondrial activity, we did not measure any significant differences in mitochondrial
membrane potential or ROS production after drug treatment (Figure 11D). The expression of
other activation markers were also not substantially affected, although a small decrease in
KLRG1 and increase in CD25 was measured (Figure 11E). Additionally, we performed a
genetic gain of function experiment and transduced activated IL-2 TE cells with retrovirus
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expressing Mfn1, Mfn2, or Opa1. Similar to enforcement of fusion pharmacologically, we found
that cells transduced with Opa1 had more mitochondria (Figure 10G) and OXPHOS (Figure
10H), than empty vector control or Mfn-transduced T cells, as well as increased overall
metabolic activity, with a predominant increase in OXPHOS over glycolysis (Figure 11F). TM
cell associated markers such as CCR7 and CD127 were increased on transduced cells, as well as
TE cell proteins, such as PD-1 (Figure 11G). We confirmed by mRNA expression that each
target gene had increased expression after transduction over the control (Figure 11G). Together
our results show that mitochondrial fusion confers a TM cell phenotype on activated TE cells even
in culture conditions that program TE cell differentiation.
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Figure 10. Enhancing mitochondrial fusion promotes the generation of memory-like T
cells.
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(A-F, I-L) OVA peptide and IL-2 activated OT-I cells were differentiated into IL-2 TE or IL-15
TM cells for 3 days in the presence of DMSO control or fusion promoter M1 and fission inhibitor
Mdivi-1 (M1+Mdivi-1) as shown in (A) pictorially. (B) Representative spinning disk confocal
images from 3 experiments of live cells generated from OT-I PhAM mice. Mitochondria are
green (GFP) and nuclei are blue (Hoechst), scale bar = 5 µm. (C) Cells stained with MitoTracker
Green and analyzed by flow cytometry. Relative MFI (left) from 6 experiments shown as mean ±
SEM (*p=0.0394, **p=0.0019) with representative histograms (right). (D) Baseline OCR and
SRC of indicated cells from 3-4 experiments shown as mean ± SEM (*p=0.0485, ***p<0.0001).
(E) CD62L expression analyzed by flow cytometry of indicated cells. Relative MFI (left) from 7
experiments shown as mean ± SEM (*p=0.0325, **p=0.0019, ***p<0.0001) with representative
histograms (right). (F) OCR of indicated cells at baseline and in response to PMA and ionomycin
stimulation (PMA+iono), oligomycin (Oligo), FCCP, and rotenone plus antimycin A (R+A).
Data represents 2 experiments shown as mean ± SEM. (G-H) OT-I cells were transduced with
either empty (Control), Mfn1, Mfn2, or Opa1 expression vectors, sorted, and cultured to generate
IL-2 TE cells. (G) Histograms representative of 4 experiments of cells stained for MitoTracker
Deep Red and (H) OCR data at baseline of transduced cells from 2 experiments. (I-L) 1-2x106
IL-2 TE cells cultured with DMSO (gray diamonds) or M1+Mdivi-1 (blue squares) were
transferred into congenic C57BL/6 recipient mice. Cell counts of donor cells recovered 2 days
later from the (I) spleen (***p=0.005) and (J) peripheral lymph nodes (pLNs, ***p=0.0006). (K)
Blood from recipient mice analyzed for % donor Kb/OVA+ cells post transfer and challenge with
1x107 CFU LmOVA by flow cytometry (*p=0.0150, n=5 per group). (L) Donor Kb/OVA+ cells
recovered from recipient spleens 6 days post challenge (*p=0.0383). (I-L) Data represents 2
experiments shown as mean ± SEM.
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Figure 11. Assessment of T cell phenotype and metabolism following pharmacological or
genetic enhancement of mitochondrial fusion.
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(A-E) IL-2 TE and IL-15 TM cells generated from OT-I mice were treated with DMSO control or
M1+Mdivi-1. (A) ECAR of indicated cells at baseline and after PMA and ionomycin
(PMA+iono) stimulation, oligomycin (Oligo), FCCP, and rotenone plus antimycin A (R+A). (B)
qPCR analysis of relative mitochondrial DNA (mtDNA) to nuclear DNA (nDNA) ratios of
indicated cells. (C) ECAR (left) and OCR/ECAR ratios (right) of indicated cells under basal
conditions. (D) Histograms of membrane potential (CMxROS, TMRM) and mitochondrial ROS
(MitoSOX) using indicated fluorescent dyes and (E) KLRG1, CD127, CCR7, and CD25 surface
marker expression of indicated cells analyzed by flow cytometry. (F-H) OT-I IL-2 TE cells were
activated and transduced with empty vector (Control), Mfn1, Mfn2, or Opa1 expressing
retrovirus. (F) ECAR, OCR/ECAR, and SRC analyzed by Seahorse EFA, (G) KLRG1, CD127,
CCR7, CD25 and PD-1 surface marker expression assessed by flow cytometry, and (H) gene
expression analysis by qPCR. (A-G) Data are shown as mean ± SEM and are representative or
(B-C, F) combined from 2-3 experiments, not significant (ns), **p<0.001, ***p<0.0001.
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T cell mitochondrial fusion improves adoptive cellular immunotherapy against tumors

A major consideration when designing adoptive cellular immunotherapy is to improve T cell
fitness during ex vivo culture, so that when T cells are re-introduced into a patient they are able
to function efficiently and persist for long periods of time (Maus et al., 2014; O'Sullivan and
Pearce, 2015; Restifo et al., 2012). Our data showed that fusion-promoting drugs created
metabolically fit T cells.

We hypothesized that enforced fusion would also enhance the

longevity of IL-2 TE cells in vivo. To test this, we adoptively transferred control and M1+Mdivi1 treated OT-I T cells into congenic mice and tracked donor cell survival. We found significantly
more drug treated T cells in the spleen (Figure 10I) and lymph nodes (Figure 10J) 2 days after
transfer. To determine if the persistence of these cells would be maintained better long term than
control cells, we infected mice with LmOVA more than 3 weeks later and measured T cell
responses against the bacteria. We found that drug-treated cells selectively expanded in response
to infection (Figure 10K) and could be recovered in significantly greater numbers in the spleen 6
days post-challenge (Figure 10L).

Next, we assessed whether these drugs could be used to promote T cell function in a model of
adoptive cell immunotherapy. We injected EL4-OVA tumor cells into mice. Then either 5 or 12
days later we adoptively transferred IL-2 TE cells that had been previously treated with DMSO or
M1+Mdivi-1. In both settings, mice that had received ‘fusion-promoted’ T cells were able to
control tumor growth significantly better than mice that had received control treated cells
(Figures 12A and B). The cytolytic ability (Figure 13A) and proliferation (Figure 13B) of the
modified IL-2 TE cells were similar to control cells, however, fusion enforced IL-2 TE cells
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expressed significantly higher levels of IFN-γ and TNF-α when restimulated with PMA and
ionomycin in vitro (Figure 13C). We also exposed activated human T cells to M1+Mdivi-1
treatment in vitro and found that activated human IL-2 TE cells had visibly more fused
mitochondria (Figure 12C), and exhibit the bioenergetic profile (Figure 12D), and surface
marker expression (Figure 12E) characteristic of TM cells, compared to control treated cells.
Parameters such as mitochondrial mass (Figure 12E) and other surface markers (Figure 13D)
were not significantly altered. These data suggest that promoting fusion in T cells may be a
translatable treatment for enhancing human therapy.
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Figure 12. Mitochondrial fusion improves adoptive cellular immunotherapy against
tumors.
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(A-B) C57BL/6 mice were inoculated s.c. with 1x106 EL4-OVA cells. (A) After 5 or (B) 12
days, 1x106 or 5x106 OT-I IL-2 TE cells cultured with DMSO or M1+Mdivi-1 were transferred
i.v. into recipient mice and tumor growth assessed. Data represents 2 experiments shown as
mean ± SEM (n=5 per group, *p<0.05, **p<0.005). (C-E) Human CD8+ PBMCs were activated
with αCD3/CD28 + IL-2 to generate IL-2 TE cells. (C) Confocal images of indicated treated cells
where mitochondria are green (MitoTracker) and nuclei are blue (Hoechst). Representative
images from 2 of 4 biological donors, scale bar = 5 µm. (D) OCR/ECAR ratios and SRC of
indicated cells from 2 separate donors shown as mean ± SEM (*p=0.0303, **p<0.005,
***p<0.0001). (E) MitoTracker Green staining and CD62L, CD45RO, and CCR7 expression
analyzed by flow cytometry shown with representative histograms from 4-6 biological replicates.
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Figure 13. Examination of mouse and human IL-2 TE cells after enforcing mitochondrial
fusion with drugs.
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(A-C) Flow cytometry analyses of IL-2 TE cells previously cultured with DMSO or M1+Mdivi-1
combined from 3 biological replicates. Cells were not subjected to further treatment with DMSO
or M1+Mdivi-1 during experiment assays. (A) Cytolysis of EL4-OVA target cells at indicated
concentrations. (B) Proliferation after restimulation with αCD3/CD28. (C) Intracellular cytokine
staining after 4 hours stimulation with PMA and ionomycin. Relative MFI (left) with mean ±
SEM and representative contour plots (right) with percentage of cytokine positive cells indicated
in gated cells and MFI in bold, *p<0.05. Gates based on unstimulated cells (not shown). (D)
Human CD8+ PBMCs were activated with αCD3/CD28 + IL-2 to generate IL-2 TE cells and
subjected to DMSO or M1+Mdivi-1 treatment. KLRG1, CD127, CD45RA, and CD25 surface
marker expression analyzed by flow cytometry shown with representative histograms from 4-6
biological replicates.
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Mitochondrial fusion promotes TM cell metabolism, but Opa1 is not required for FAO

Our data showed that Opa1 was a necessary regulator of TM cell development, but the question
of precisely how Opa1 acted to support TM cells remained. We hypothesized that mitochondrial
fusion, via Opa1 function, was needed for FAO, as the engagement of this pathway is a
requirement for TM cell development and survival (Pearce et al., 2009; van der Windt et al.,
2012; van der Windt et al., 2013). This hypothesis was not only based on our observations that
these two processes seemed to be linked in TM cells, but also on a recent study showing that
mitochondrial fusion is important for efficient FAO via lipid droplet trafficking under starvation
conditions (Rambold et al., 2015). We treated IL-2 TE and IL-15 TM cells with M1+Mdivi-1 or
vehicle and then measured OCR in response to etomoxir, a specific inhibitor of mitochondrial
long chain FAO (Deberardinis et al., 2006), and mitochondrial inhibitors. We found that the
increased OCR and SRC evident in these cells after M1+Mdivi-1 treatment was due to
augmented FAO (Figures 14A and 15A). IL-2 TE cells transduced with Opa1 also exhibited
enhanced OCR that decreased in the presence of etomoxir compared to control cells (Figure
14B). Bone marrow derived macrophages (BM-Macs) cultured with M1+Mdivi-1 also increased
OCR and SRC to levels similar as M2 polarized macrophages, which engage FAO much like TM
cells do (Figure 15B) (Huang et al., 2014). Importantly, M1+Mdivi-1 treatment did not increase
OCR (Figure 14C) and did not affect ECAR (Figure 15C) in Opa1-/- IL-2 TE cells compared to
controls, suggesting a requirement for Opa1 in augmenting OCR and FAO. However, in contrast
to what we expected, when we assessed bioenergetics of Opa1+/+ and Opa1-/- IL-2 TE cells
(Figure 14D) and ex vivo isolated TE cells (Figure 14E), we found that both cell types are
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equally responsive to etomoxir. Our results show that while Opa1 could promote FAO in T cells,
it was not compulsory for engagement of this metabolic pathway.
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Figure 14. Fusion promotes memory T cell metabolism, but Opa1 is not required for FAO.

(A-E) OCR measured at baseline and in response to media, etomoxir (Eto) and other drugs as
indicated of (A) IL-2 TE cells cultured in DMSO or M1+Mdivi-1, (B) control or Opa1
transduced IL-2 TE cells, (C) Opa1+/+ and Opa1-/- IL-2 TE cells cultured in DMSO or M1+Mdivi1 (D) or without drugs, and (E) ex vivo donor OT-I Opa1+/+ and Opa1-/- day 7 TE cells derived
from LmOVA infection. (A-E) Data representative of 2 independent experiments shown as mean
± SEM (***p<0.0001).
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Figure 15. Bioenergetics analysis after promoting mitochondrial fusion in T cells and
macrophages.

(A) OCR of IL-15 TM DMSO or M1+Mdivi-1 treated cells measured at baseline and in response
to media, etomoxir (Eto), oligomycin (Oligo), FCCP, and rotenone plus antimycin A (R+A). (B)
Bone marrow derived macrophages were cultured overnight with IL-4 (M2) or without (M0) and
either DMSO or M1+Mdivi-1 overnight. OCR analyzed at baseline and after injection of
mitochondrial inhibitors as indicated. (C) Baseline ECAR relative to DMSO controls of IL-2 TE
Opa1+/+ and Opa1-/- cells cultured in DMSO or M1+Mdivi-1. (A-C) Data are shown as mean ±
SEM and are representative of 2-3 experiments.
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Mitochondrial cristae remodeling signals metabolic adaptations in TM and TE cells

Although both Opa1+/+ and Opa1-/- IL-2 TE cells could equally engage FAO (Figure 14D), we
observed that ECAR was significantly augmented in the Opa1-/- cells both in vitro and ex vivo
(Figure 16A). Furthermore, unlike control cells, we observed no additional drop of OCR in
Opa1-/- IL-2 TE cells after the addition of oligomycin (Figure 16B), suggesting that in the
absence of Opa1, only FAO supports OXPHOS, and that oxidation of other substrates, such as
glucose-derived pyruvate, are not utilized for mitochondrial ATP production in this setting. We
cultured Opa1+/+ and Opa1-/- IL-2 TE cells with
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C-labeled glucose and traced

cycle metabolites. We found that while the percent of

13

13

C into TCA

C-labeled pyruvate was higher in the

Opa1-/- T cells, the frequency of 13C-labeled TCA cycle intermediates was significantly reduced
in the Opa1-/- T cells compared to controls (Figures 16C and 17A), a result that is supported by
their higher ECAR (Figure 16A). These data suggested that without mitochondrial fusion,
pyruvate is preferentially secreted as lactate, rather than oxidized in the mitochondria. Therefore,
we questioned whether FAO was a ‘default’ pathway for mitochondria in a resting, or fused state
(i.e. Opa1 sufficiency), and that the induction of aerobic glycolysis is a major downstream effect
of fission (i.e. Opa1 deficiency). If this were the case, then a balance between fission and fusion,
modulated by proteins such as Opa1, could act as a primary signal to dictate the metabolic
phenotype of T cells. In support of this idea, T cells from polyclonal T cell-conditional deleted
Opa1 animals had higher ECAR and an increased proportion of CD8 T cells with an activated
effector phenotype in the basal state based on surface marker expression (Figure 17B).
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Opa1 is critical for inner mitochondrial membrane fusion, but also for other processes like cristae
remodeling (Cogliati et al., 2013; Frezza et al., 2006; Varanita et al., 2015). We observed major
changes in cristae morphology in the Opa1-/- T cells (Figure 8B). Given the importance of Opa1
function in TM cell development (Figure 8), we further assessed cristae morphology in TE and
TM cells isolated ex vivo after LmOVA infection (Figure 16D), as well as in IL-2 TE and IL-15
TM cells (Figure 16E), and found that TE cells had many cristae with what appeared to be
slightly wider, or more loosely organized intermembrane space, than TM cells. It has been found
that Opa1 overexpression induces cristae tightening and close association of ETC complexes in
the inner mitochondrial membrane (Civiletto et al., 2015; Cogliati et al., 2013). Therefore, we
surmised that in the absence of Opa1, cristae disorganization leads to dissociation of ETC
complexes, and subsequently less efficient ETC activity, in T cells (Figure 8C). We assessed
OCR after oligomycin in relation to OCR after rotenone plus antimycin A treatment (i.e. proton
leak), which indicates the coupling efficiency of OXPHOS with mitochondrial ATP production.
Consistent with decreased OXPHOS efficiency, we observed increased proton leak in Opa1-/- T
cells compared to control cells (Figure 16F). This was also true for ex vivo isolated TE cells
when compared to TM cells (Figure 16G), as well as IL-2 TE and IL-15 TM cells (Figure 16H).
Together these data suggest that there are cristae differences between TE and TM cells which may
contribute to their distinct metabolic phenotypes.

We reasoned that fusion renders tightly configured cristae, which results in closely associated
ETC complexes and efficient OXPHOS (Patten et al., 2014), producing conditions that favor the
entrance of pyruvate into the TCA cycle. In this situation, NADH generated from the TCA cycle
is able to easily donate electrons to complex I, which are passed efficiently along the ETC. Our
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data suggested that this predominantly occurs in TM cells. However, if electron transport across
the ETC becomes less efficient, which could be caused by physical separation of the individual
complexes due to cristae remodeling via mitochondrial fission, then electrons could linger in the
complexes and imbalance redox reactions. NADH levels would build, slowing forward
momentum of the TCA cycle. To restore redox balance, cells could augment glycolysis and
shunt pyruvate as excreted lactate (i.e. aerobic glycolysis), which would regenerate NAD+ from
NADH in the cytosol. We speculated that this is what occurs in TE cells. Correlating with this
idea, we previously reported that TE and TM cells have different ratios of NAD+/NADH (i.e.
redox balance), with TM cells maintaining higher NAD+/NADH than TE cells. We also showed
that NADH levels dramatically rise in TM cells compared to TE cells when exposed to
rotenone/antimycin A, indicating that TM cells continually consume more NADH for the purpose
of donating electrons to the ETC (van der Windt et al., 2012). Together our data suggested that
fission and fusion events regulate cristae remodeling, which could alter ETC efficiency and
redox balance, ultimately controlling metabolic adaptations in T cells.

To more thoroughly examine this idea, we assessed cristae morphology in TE and TM cells by
EM following TCR stimulation. We hypothesized that if cristae remodeling acts to induce
aerobic glycolysis, changes in cristae structure could be visualized following T cell activation.
TM cells rapidly augment aerobic glycolysis when restimulated (van der Windt et al., 2013). We
activated IL-15 TM cells with αCD3/CD28-conjugated beads (Figure 16I), or with PMA and
ionomycin (Figure 17C), in the presence or absence of Mdivi-1, to modulate activity of the
mitochondrial fission protein Drp1 (Cassidy-Stone et al., 2008). We observed dramatic changes
to cristae morphology by EM, with the intermembrane space widening over time in control cells

114

in comparison to drug treated cells. These data are consistent with the hypothesis that fissioninduced mitochondrial cristae remodeling supports metabolic reprogramming in T cells.

TM cells maintain tight cristae with closely associated ETC complexes
Our data suggested that unlike TE cells, TM cells have tight cristae with close association of the
ETC complexes. To investigate this biochemically, we treated native lysates of IL-2 TE and IL15 TM cells with increasing concentrations of digitonin to disrupt all cellular membranes
(including mitochondrial). The crude membrane-bound fraction was separated from solubilized
proteins by centrifugation. Both pellet and soluble supernatant fractions were loaded on a
denaturing reducing gel and then probed for various mitochondrial proteins by western blot. We
found that mitochondria in IL-2 TE cells were susceptible to digitonin disruption, indicated by
the fact that ETC complex proteins became less detectable in the pellet, and amplified in the
soluble fraction, in 0.5% detergent (Figures 16J and 17D). This was in contrast to IL-15 TM
cells, where ETC proteins did not solubilize to the same extent as those in IL-2 TE cells into the
supernatant, even when 2% digitonin was used. To investigate whether this phenomenon was
unique to the mitochondrial compartment, we also probed for the ER integral protein calnexin
and found that it solubilized similarly in 0.5% digitonin in both cell types. Overall these data
suggest that there is more exposed mitochondrial membrane between proteins in IL-2 TE cells
than in IL-15 TM cells, and correlate with the idea that TM cells have tight cristae which would
yield efficient ETC activity, while TE cells have looser cristae with less efficient ETC activity,
ultimately supporting their distinct metabolic phenotypes.
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Mitochondrial fission in activated immune cells facilitates aerobic glycolysis
Our data suggested that cristae remodeling, through fission and fusion events, was a mechanism
to regulate efficient OXPHOS and FAO in TM cells, as well as the induction of aerobic
glycolysis in TE cells. To more directly test this idea, we assessed ECAR of IL-15 TM cells that
were stimulated with αCD3/28-conjugated beads in the presence or absence of Mdivi-1. We
found that when mitochondrial fission protein Drp1 was inhibited with Mdivi-1, T cell activation
did not robustly increase aerobic glycolysis when compared control cells (Figure 16K), which
correlated with our EM data (Figure 16I). Since fission can be associated with cell division
(Marsboom et al., 2012; Taguchi et al., 2007), we wanted to test our idea in a non-proliferating
cell type that substantially augments aerobic glycolysis upon stimulation (Everts et al., 2014;
Everts et al., 2012; Krawczyk et al., 2010). We stimulated bone marrow derived dendritic cells
(BM-DCs) and macrophages (BM-Macs) with lipolysaccharide (LPS) with or without interferon
(IFN)-γ in the presence or absence of Mdivi-1 and measured ECAR. Aerobic glycolysis was
curtailed in both BM-DCs and BM-Macs following stimulation when Drp1 was inhibited
(Figure 16L). The blunted ECAR in the Mdivi-1 treated cells correlated with significantly
decreased nitric oxide synthase 2 (Nos2) protein expression in the BM-Macs (Figure 16M),
indicating that their activation was also repressed. These data indicate that cristae remodeling
and/or fission acts as a signal to drive the induction of aerobic glycolysis, and subsequent cellular
activation via Drp1.
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Figure 16. Mitochondrial cristae remodeling signals metabolic pathway engagement.
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(A) Basal ECAR of OT-I Opa1+/+ and Opa1-/- IL-2 TE cells (left) and day 7 TE cells isolated ex
vivo after adoptive transfer from LmOVA infection (right). Data combined from 2-3 experiments
(*p=0.0412, ***p<0.0001). (B) OCR at baseline and after indicated drugs, representative of 2
experiments shown as mean ± SEM, and (C) D-Glucose-13C1,2 trace analysis of OT-I Opa1+/+
and Opa1-/- IL-2 TE cells. Each lane represents separate mice with a technical replicate. (D) EM
analysis of mitochondrial cristae from TE and TM cells isolated after LmOVA infection and (E)
in vitro cultured IL-2 TE and TM cells. Data representative of 2 experiments, scale bar = 0.25 µm.
Relative proton leak (ΔOCR after oligomycin and subsequent injection of rotenone plus
antimycin A) of (F) Opa1+/+ and Opa1-/- IL-2 TE, (G) infection elicited TE and TM, and (H) IL-2
TE and IL-15 TM cells. (F-H) Data combined from 2-4 experiments shown as mean ± SEM
(p**<0.005, ***p<0.0001). (I) EM analysis of IL-15 TM cell-mitochondrial cristae before and
after αCD3/CD28-conjugated bead stimulation over hours, scale bar = 0.2 µm and represents one
experiment. (J) Immunoblot analysis of ER protein Calnexin and ETC complexes (CI-NDUFB8,
CII-SDHB, CIII-UQCRC2, CIV-MTC01, CV-ATP5A). Equivalent numbers of IL-2 TE and IL15 TM cells were lysed in native lysis buffer followed by digitonin solubilization of intracellular
membranes. Pellet (P) and solubilized supernatant (S) fractions were resolved on a denaturing
gel. Data representative of 2 experiments. (K) IL-15 TM cell, (L) bone marrow-derived dendritic
cell (BM-DCs) and macrophage (BM-Macs) % ECAR measured at baseline and after media,
αCD3/CD28-conjugated bead, LPS, or LPS+IFN-γ injection as indicated. Data are baselined
prior to or right after injection with stimuli. (M) BM-Macs stained for intracellular Nos2 protein
by flow cytometry with MFI values (left) and representative histogram (right). (K-M) Data
shown as mean ± SEM and represent 2-3 experiments (***p<0.0001).
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Figure 17. T cell activation induces cristae remodeling that regulates metabolism.
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(A) Activated Opa1+/+ and Opa1-/- IL-2 TE cells were cultured overnight with D-Glucose-13C1,2
and traced for incorporation by mass spectrometry. Heat map representation of % labeled
carbons in listed metabolites. (B) Spleens from either polyclonal wild-type (+/+) or Opa1
deficient T cell animals (-/- Opa1 T) were isolated and surface marker expression assessed
(CD44, CD62L on CD3+ CD8+ gates) by flow cytometry (top) or were further purified for CD8
T cells to assess OCR and ECAR at baseline (below) by Seahorse EFA. Data presented with
mean ± SEM from n=6 per genotype, ***p<0.0001. (C) EM images of IL-15 TM cell
mitochondria over time before and after PMA and ionomycin stimulation from one experiment.
Scale bar = 0.5 µm. (D) Immunoblot analysis of ETC complexes (CI-NDUFB8, CII-SDHB,
CIII-UQCRC2, CIV-MTC01, CV-ATP5A) and OMM protein Tom20. Equivalent numbers of
IL-2 TE and IL-15 TM cells lysed in native lysis buffer followed by digitonin solubilization of
intracellular membranes. Pellet (P) and solubilized supernatant (S) fractions were resolved on a
denaturing gel. Second experiment represented from Figure 16J.
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Discussion

Although TM cells rely on FAO for development and survival, precisely why TM cells utilize
FAO and the signals that drive the induction of aerobic glycolysis in TE cells remain unclear. Our
data suggest that manipulating the structure of a single organelle can have profound
consequences that impact metabolic pathway engagement and ultimately, the differentiation of a
cell. We found that Opa1 regulated tight cristae organization in TM cells, which facilitated
efficient ETC activity and a favorable redox balance that allowed continued entrance of pyruvate
into mitochondria. We originally hypothesized that Opa1 would be an obligate requirement for
FAO. However, we found that Opa-1-/- IL-2 TE cells and ex vivo TE cells generated during
infection utilized FAO to the same level as cells expressing Opa1. While this was true for TE
cells, this may not be the case for TM cells, whose survival is severely impaired in vitro and in
vivo when deficient in Opa1. It is possible that Opa1-/- T cells are unable to form TM cells
because they cannot efficiently engage FAO under the metabolic constraints imposed during TM
cell development. Previous studies point to the existence of a ‘futile’ cycle of fatty acid synthesis
(FAS) and FAO within TM cells (Cui et al., 2015; O'Sullivan et al., 2014) whereby carbon
derived from glucose oxidation is used to build fat that is subsequently burned by mitochondria
for fuel. TM cells have a lower overall metabolic rate than TE cells, and tightly configured cristae
might be important to ensure that any pyruvate generated will efficiently feed into the TCA cycle
not only for reducing equivalents, but also for deriving citrate for FAS. Without tight cristae and
efficient ETC activity, electrons may loiter in the complexes, causing more ROS, which could be
damaging (Chouchani et al., 2014), but also provide signals that drive cell activation (Sena et al.,
2013).
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We did not observe a defect in TM cell survival in Mfn1 and Mfn2 deficient T cells, but this does
not exclude the possibility that OMM fusion or additional activities ascribed to each of these
proteins are not important. Mfn1 and Mfn2 form both homotypic and heterotypic interactions,
suggesting that in the absence of one protein, the other can compensate (Chen et al., 2003). Our
preliminary data assessing Mfn1/2 expression in Mfn1-/- and Mfn2-/- T cells indicate that this
might be occurring (data not shown). However, our results clearly show that unlike Opa1-/- T
cells, in vitro cultured Mfn1-/- or Mfn2-/- T cells do not have a survival defect when differentiated
in IL-15 (Figure 8A), even though, like Opa1-/- T cells, they are more glycolytic and OXPHOSimpaired compared to controls (data not shown). Further investigation using Mfn1/2 double
knockouts is underway in our laboratory to examine whether a lack of both proteins, and
presumably total OMM fusion, impairs TM cell development in similar fashion as deficiency in
inner membrane fusion. Our imaging data showed that TM cells maintained extended fused
mitochondrial networks, suggesting that OMM fusion also has a compulsory role in TM cell
development. However, unlike Opa1, retroviral expression of Mfn1 and Mfn2 did not confer a
TM cell phenotype in TE cells. This could be due to the fact that an increase in OMM fusion,
without a concomitant increase in inner membrane fusion, would still yield an overall loose
cristae morphology and redox state that by default, results in sustained excretion of lactate.

The question of what signals drive T cell structural remodeling of mitochondria in the first place
still remains. In the case of TM cell development, initial withdrawal of activating signals and
growth factors may induce fusion, consistent with previous reports that starvation induces
mitochondrial hyperfusion (Rambold et al., 2015; Rambold et al., 2011b), an effect we also
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observe in TE cells after IL-2 withdrawal (data not shown). However, pro-survival signals from
cytokines such as IL-15 or IL-7 are needed to sustain TM cell viability and metabolically remodel
these cells for FAS and FAO via increased CPT1a (van der Windt et al., 2012) and aquaporin 9
expression (Cui et al., 2015). Factors such as these may enforce the fused state and would be
consistent with our observations that activated T cells subsequently cultured in IL-15 become
more fused over time (Figure 6D). Another possibility is that Opa1 is activated via sirtuin 3
(SIRT3) under metabolically stressful conditions (Samant et al., 2014). Sirtuins are posttranslational modifiers that are activated by NAD+, directly tying their activity to the metabolic
state of the cell (Houtkooper et al., 2012; Wang and Green, 2012). Our previous work
demonstrated that the available NAD+ pool is higher in TM cells (van der Windt et al., 2012),
which could correlate with this scenario.

In TE cells we see an immediate activation of Drp1, prior to seeing a fissed phenotype, and
inhibition of Drp1 prevents ECAR induction after activation. TCR signals induce Ca2+ flux that
activates the phosphatase activity of calcineurin (Smith-Garvin et al., 2009), which in turn
dephosphorylates Drp1 at Ser637, leading to its activation (Cereghetti et al., 2008). Initial Drp1
activation could facilitate some level of fission and cristae remodeling, tipping off aerobic
glycolysis via the initial shunting of pyruvate to lactate. Our data (Figure 6E) showed that Drp1
is phosphorylated at its activating site Ser616 at day 1 after activation, which preceded
recognizable mitochondrial fragmentation (Figure 6C). Our preliminary data did not show overt
mitochondrial fragmentation in the initial hours after TLR stimulation of DC or macrophages
(data not shown), but this does not exclude the possibility that Drp1 is actively mediating more
subtle changes to mitochondrial structure that are not discernable by confocal microscopy. For
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example, Drp1 also has been found to affect cristae structure by altering the fluidity of the
mitochondrial membrane (Benard et al., 2007; Benard and Rossignol, 2008). Although Drp1 has
been implicated in mitochondrial positioning at the immune synapse (Baixauli et al., 2011),
lymphocyte chemotaxis (Campello et al., 2006), and ROS production (Roth et al., 2014) during
T cell activation, our data suggest that in addition to these processes, fission underlies the
reprogramming of cells to aerobic glycolysis.

We show that IL-2 TE cells have a mitochondrial structure that is more susceptible to digitonin
disruption when compared to IL-15 TM cells, which suggests a more exposed membrane with
less densely packed protein complexes. This relatively enhanced permeability however, does not
mean that their mitochondria are damaged, or unable to function. In fact, although TE cells have
less efficient OXPHOS in terms of how it is coupled to ATP synthesis, TE cells are very
metabolically active with high OCR and ECAR (Chang et al., 2013; Sena et al., 2013). Our
experiments involving pharmacological enforcement of mitochondrial fusion promoted OCR and
SRC (and ECAR, albeit to a lesser extent) in IL-2 TE cells. The drug modified cells maintained
full TE cell function with no effect on their cytolytic ability or proliferation, but possessed
enhanced cytokine expression. Fusion and/or cristae tightening boosted the TE cells’ oxidative
capacity, endowing them with longevity and persistence, while their higher aerobic glycolysis
supported increased cytokine production, which may explain their superior antitumor function.

Our data suggest a model where morphological changes in mitochondria are a primary signal that
shapes metabolic reprogramming during cellular quiescence or activation. We speculate that
fission associated expansion of cristae as a result of TCR stimulation physically separates ETC
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complexes, decreasing ETC efficiency. With delayed movement of electrons from complex I
down the ETC, NADH levels rise in the mitochondria, slowing forward momentum of the TCA
cycle and cause an initial drop in ATP. To correct redox balance, cells will export pyruvate to
lactate to regenerate NAD+ in the cytosol, which can enter the mitochondria through various
shuttles to restore redox balance (Dawson, 1979) and increase flux through glycolysis to restore
ATP levels, all contributing to the Warburg effect in activated T cells. When cristae are tightly
configured, the ETC works efficiently and maintains entrance of pyruvate into the mitochondria
with a favorable redox balance. In this case, cristae morphology as a result of fusion directs TM
cell formation and retains these cells in a quiescent state. Thus, mitochondrial dynamics control
the balance between metabolic pathway engagement and T cell fate.
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Figure 18. Mitochondrial dynamics controls T cell fate through metabolic programming.
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